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ABSTRACT 
 
 The level of torsion in double-stranded DNA regulates base-pair stability and 
DNA conformation. It is important in initiation and regulation of specific DNA metabolic 
processes as well as chromatin assembly. High mobility group proteins (HMGB) are 
architectural proteins whose HMG DNA binding domains confer significant preference 
for distorted DNA, such as supercoiled DNA and 4-way junctions. HMGB proteins play 
a role in transiently regulating or conserving DNA torsion. Topoisomerases regulate 
DNA supercoiling, which has been argued to provide a coherent explanation for the main 
modes of transcriptional control - stringent control, growth-rate control and growth-phase 
control during normal cell growth.  
 In this study, we have shown that HMO1, a Saccharomyces cerevisiae HMGB 
protein which is required for normal growth, plasmid maintenance and regulating the 
susceptibility of yeast chromatin to nuclease, binds linear duplex DNA but has little 
preference for DNA with altered conformations. The divergent box A binds DNA and 
contributes structure-specific binding. Unlike most HMGB proteins, HMO1 does not 
supercoil relaxed DNA in the presence of topoisomerase. Casein Kinase II 
phosphorylates HMO1, altering its DNA binding properties. We have also shown that 
deletion of the highly basic C-terminal tail of HMO1 localizes this otherwise nuclear and 
cytoplasmic protein only to the cytoplasm. As the C-terminally truncated HMO1 has 
been reported to rescue the hmo1 knockout phenotype, we conclude that the main 
function of HMO1 lies in the cytoplasm, and not in the nucleus.   
 Vaccinia topoisomerase I relaxes supercoiled DNA. We have shown that it 
interacts with enrofloxacin, a fluoroquinolone antibiotic which otherwise targets DNA 
 x
gyrase and topoisomerase IV. Enrofloxacin inhibits DNA relaxation by Vaccinia 
topoisomerase I. When presented with relaxed DNA, the enzyme executes the reverse 
reaction, supercoiling the DNA. Enrofloxacin does not interfere with the catalytic 
cleavage site of Vaccinia topoisomerase I or its ability to bind DNA. The mechanistic 
implication of these observations is that protein-DNA contacts downstream of the 
cleavage site must contribute to DNA supercoiling, contrary to the free rotation 
mechanism proposed for DNA relaxation. 
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CHAPTER 1 
INTRODUCTION 
 DNA topology is critical in cellular processes such as replication, transcription, 
recombination, chromosome condensation and much more. DNA topology must therefore 
be fine-tuned to allow these critical processes to optimally proceed as deemed. High 
Mobility Group proteins (HMG) are DNA architectural proteins that have been shown to 
participate in these processes and have been shown to introduce supercoils into closed 
circular DNA in the presence of topoisomerase. Topoisomerases are proteins that 
remove/regulate DNA supercoiling, playing a critical role in the above mentioned cellular 
processes. In fact, drugs that interfere with the function of topoisomerases are in wide use 
both clinically and in research. We are describing HMO1, a Saccharomyces cerevisiae 
HMG protein that differs in its activity from previously characterized homologs in that it 
does not supercoil DNA. We also show unusual properties of  Vaccinia topoisomerase I; 
this enzyme interacts with a fluoroquinolone drug enrofloxacin, which causes it to 
execute the reverse reaction, supercoiling DNA when presented with closed circular 
DNA, as opposed to relaxing supercoiled DNA.  
High-Mobility-Group (HMG) Proteins  
 HMG are a family of ubiquitous proteins that constitute a significant fraction of 
non-histone nuclear proteins. They were first extracted from nuclei with 0.35 M NaCl by 
the British scientist H. M. Goodwin, and the name indicates that they are small proteins 
that run fast in SDS-polyacrylamide gels [1]. They consist of three subfamilies: HMGA, 
HMGB, and HMGN. HMG proteins are united by a common theme in that they alter the 
local conformation of DNA or nucleosomes, thus increasing their accessibility and 
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plasticity, and facilitating and enhancing various DNA-dependent activities such as 
transcription, replication, recombination and DNA repair [2-5]. The three subfamilies 
have a characteristic motif, such as the HMG-box in HMGBs, the AT-hook in HMGAs, 
and the nucleosomal binding domain in HMGNs. My dissertation will focus on the 
HMGB group of proteins to which HMO1, the protein of my dissertation research, 
belongs.  
Classification of HMGB Proteins 
 HMGB proteins contain one or more homologous repeats of the ~80-amino acid 
sequence HMG box and are classified into two families based on their abundance, 
function and DNA specificity of this conserved region [2, 6-7]. The moderately 
sequence-specific family are transcription factors that usually contain a single HMG box 
and recognize dsDNA. They are typified by transcription factors such as sex-determining 
factor SRY and lymphoid enhancer factor LEF-1 [8, 9]. The non-sequence specific 
family binds DNA without sequence preference but instead structural preference. They 
are represented by the so-called architectural factors HMGB1/2, ubiquitous proteins in 
vertebrates, and the Saccharomyces cerevisiae non-histone chromosomal protein 6A and 
6B (NHP6A/B) [10]. HMGB1/2 have two HMG boxes (A and B) and a long acidic tail 
containing aspartic or glutamic acid residues, linked to the HMG boxes by a region of 
basic residues. Most HMG-box proteins in organisms other than vertebrates have only a 
single HMG box which sometimes is accompanied by an acidic tail (e.g., HMG-D, 
HMG-Z [11,12]), but not always (e.g., NHP6A/B, [13]). NHP6A/B contains a highly 
basic amino acid region in front of the HMG box that has been shown to be important for 
elevated DNA binding affinity [14].  
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Structure of HMGB Proteins 
 Several structures of HMG boxes from both the non-sequence specific subfamily 
and the sequence specific subfamily of proteins have been determined in the presence 
and/or absence of DNA. Non-sequence specific HMG boxes for which structures have 
been determined in the absence of DNA include HMGB1 box A [15], HMGB1 box B 
[16, 17], HMG-D [18] and NHP6A [19]. Masse et al., later determined the structure of 
NHP6A in the presence of DNA [20]. The structure of SOX4, a sequence specific HMG 
box protein was determined in the absence of DNA [21], while the structures of two 
sequence specific HMG proteins, SRY and LEF-1 were determined in the presence of 
their cognate DNA recognition sequence [22, 23]. 
 The structures of both sequence specific and non-sequence specific homologs 
have been determined to have the same general global fold, characterized by a 3-
dimensional, L-shaped structure with three α-helices (reviewed in [4, 24-25]). The long 
arm consists of the amino-terminal extended peptide and helix III, while the shorter arm 
comprises two central helices I and II. A hydrophobic core of conserved aromatic 
residues from the three α-helices is maintained at the apex of the L-shaped structure. This 
region has the most highly conserved amino acid residues in the HMG boxes. Outside the 
hydrophobic core, the conservation scores decline, getting lower gradually with 
procession toward the end of either arm of the protein. This trend probably reflects the 
relative importance of the various regions of the protein for adopting the HMGB fold.  
Binding Targets of HMG Boxes 
 The structure of the sequence specific proteins show the DNA to be greatly 
distorted in the region of protein contact, with SRY introducing a bend of 80° [23] while 
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LEF-1 introduces a 120° bend [9]. The HMG box binds to the minor groove of B-form 
DNA with its concave face and causes bending by partial insertion of hydrophobic 
residues close to the amino-terminus of helix I into the minor groove of the DNA. As a 
consequence, the DNA is severely underwound and widened, thus increasing the protein-
DNA interface. The DNA is kinked towards the opposing major groove which is thereby 
highly compressed. Hydrophobic interactions as well as hydrogen bonds between the 
proteins and the DNA sequence mediate the specificity of this class of HMGB protein 
[20].  
Determinants of Sequence-Specific Versus Non-Sequence Specific HMGB Proteins 
 Detailed structures of the non-sequence specific proteins have reiterated the main 
features of interaction but also reveal interesting and important differences. Extensive 
phylogenetic analysis by Masse et al., revealed determinants of sequence-specific versus 
non-sequence specific HMGB proteins [20]. Using NHP6A as a common reference 
frame, these authors noted that the residue in position 57 shows the most statistically 
significant correlation to DNA recognition type (Figure 1.1). For non-sequence specific 
HMGB proteins, this position is almost always negatively charged and most likely to be 
involved in stabilizing the fold of helix 2, as it is often surrounded by positively charged 
residues. Conversely, a variety of residues are present in this position in sequence 
specific HMGB proteins. Other negatively charged residues in helix 1 and helix 3 show 
correlation with non-sequence specificity, but not as significant as the residue in position 
57. These authors speculated that these negative charges may be involved in restricting 
the path of the DNA on the protein through electrostatic repulsion, a function that 
sequence specific DNA-binding proteins can achieve by forming sequence specific  
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NHP6A  PKRALSAYMFFANENRDIVRSENPD  ITFGQVGKKLGEKWKALTPEEKQPYEA 
HMGB1  PRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFED 
HMGD   PKRPLSAYMLWLNSARESIKRENPG  IKVTEVAKRGGELWRAM  KDKSEWEA  
           
HMO1   PKKPLTVFFAYSAYVRQELREDLPP  LSSTEITQEISKKWKELSDNEKEKWKQ 
  
LEF-1  IKKPLNAFMLYMKEMRANVVAECTL  KESAAINQILGRRWHALSREEQAKYYE 
SRY    VKRPMNAFIVWSRDQRRKMALENPR  MRNSEISKQLGYQWKMLTEAEKWPFFQ  
UBF    PKKPLTPYFRFFMEKRKYAKLH PE  MSNLDLTKILSKKYKELPEKKKMKYIQ 
 
Figure 1.1 Alignment of HMG-box helices I and II. For non-sequence specific proteins, 
S. cerevisiae NHP6A along with box A of rat HMGB1, Drosophila melanogaster HMGD 
and box B of S. cerevisiae HMO1. Sequence specific proteins are mouse LEF-1, human 
SRY, and Xenopus laevis UBF box A. Residues corresponding to positions 29, 48 and 57 
of NHP6A helices I and II, respectively, are in bold.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29                                                           48                       57
Helix I Helix II 
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hydrogen bonds with DNA. Another important position that correlates to specificity of 
the HMGB proteins is 48 which is almost always a bulky hydrophobic residue in non-
sequence specific proteins. In the structure of NHP6A and HMG-D, it has been shown 
that it contributes to DNA bending by re-directing the trajectory of the DNA as it exits 
the protein [20, 22]. This exit wedge has also been shown to be the critical determinant 
for selective binding by both HMGB1 Box A and NHP6A to pre-bent DNA resulting  
from cisplatin modification or a bulge. In sequence specific proteins, this position usually 
has a hydrophilic, often charged residue which makes specific hydrogen bonds to the 
cognate DNA. These specific hydrogen bonds within the minor groove are believed to 
direct the sequence specific HMGB proteins to specific DNA targets. The means by 
which non-sequence specific HMGB proteins pick their B-DNA target seems different 
from sequence specific DNA binding proteins. Looking at NHP6A and HMG-D 
structures, it appears that Met29 is of primary importance for selecting a deformable 
base-pair step in B-DNA. Clear and striking evidence of the difference in modes of 
recognition between sequence specific and non- sequence specific homologs is seen 
when the structures of NHP6A-DNA and SRY-DNA is compared (Figure 1.2). The two 
proteins bind to the related DNA sequence in opposite orientations and 1 bp step shifted 
[20, 23].  
The Role of HMG Box Basic Extensions 
 Basic extensions found either C- or N-terminal to the HMG box are known to 
increase the bending capacity and DNA-binding affinity of the HMG box. For example, 
the 16 basic amino acids found in the N-terminus of the NHP6A HMG box is required for 
stable complex formation on both linear DNA and DNA minicircles. At high  
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           NHP6A                                                          SRY 
       
Figure 1.2 Cocrystal structure of NHP6A and SRY with DNA. Comparison of solution 
structures of NHP6A-DNAsry and SRY-DNA (Protein data bank (PDB) accession 
numbers 1LWM and 1HRZ respectively) [20, 23]. DNA is shown in backbone model to 
clearly demonstrate that the two proteins (shown in ribbon form) bind related DNA 
sequence in opposite orientations.  
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concentrations, mutants lacking the N-terminus are able to promote minicircle formation 
and Hin invertasome assembly, but they are unable to form stable complexes with DNA, 
co-activate transcription, and complement the growth defect of ∆nhp6a/b mutants [14]. 
Basic C-terminal extensions stabilize binding of HMG-D and LEF-1 by binding in the 
major groove opposite the distorted minor grove [22, 26].  
HMGB1/2 Acidic C Terminal Tail  
 The HMGB1/2 acidic tail has been shown to lower the affinity of the HMG boxes 
for most DNA substrates, such as linear DNA, supercoiled DNA and four-way junctions. 
Interestingly, the tail is essential for structure-selective DNA-binding of the HMG boxes 
to DNA minicircles, and it has little effect on the affinity for DNA minicircles compared 
to other DNA substrates in vitro [27]. However, it was not established whether this is a 
consequence of interaction of the tail with the HMG box(es) or the basic extension region 
or simply charge repulsion. Thomsen et al. [28] showed that the interactions of the basic 
N-terminal and acidic C-terminal domains of the maize HMGB1 may contribute to the 
regulation of the DNA interactions of the protein. A similar phenomenon was also            
observed for the Arabidopsis HMGB1 and HMGB4 [28]. This led the authors to argue 
that the interaction of the variable terminal domains of the different  plant HMGB 
proteins could serve as a molecular mechanism involved in the fine tuning of the 
functional properties of these architectural proteins depending on the structural 
requirements of specific nucleoprotein complexes.  
 Shirakawa et al. showed that the acidic tail may be involved in nuclear retention 
of HMGB2 [29]. In cells overexpressing HMGB1, the protein was shown to bind to a 
minichromosome derived from the transfected reporter plasmid, substituting for linker 
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histone H1, and to stimulate transcription from the reporter plasmid accompanied by 
decondensation of the minichromosome structure [30]. In addition, the acidic tail is 
required for stimulation of transcription [31] and it has recently also been demonstrated 
to stimulate nucleosome sliding by the chromatin remodeling factor ACF/CHRAC [32]. 
This study also showed that the HMGB1 acidic tail is a dominant factor involved in its 
binding to the nucleosome and is required for binding to nucleosome linker DNA.  
The Diverse Roles of HMGB1 in vivo 
 HMGB1 protein has been shown to interact with a diverse set of proteins. It plays 
an important role in transcription by interacting with several transcription factors, viral 
replication proteins, the RAG1 recombinase, and steroid receptors [33]. Hmgb1 knockout 
mice die soon after birth with defects in the function of steroid receptors revealing that 
the gene is essential [34]. HMGB1 is the most mobile nuclear protein [35]. Manfredi and 
Bianchi (review in [36]) referred to HMGB1 as a chromatin chaperone that uses no 
energy besides Brownian motion, because it wanders where it is required within 
reasonable time, does its job and then leaves. 
Extracellular HMGB1 Signals to Multiple Cellular Targets 
 Although HMGB1 was considered to be a nuclear protein, biochemical and 
immunological early studies performed by Bustin et al. suggested that its intracellular 
distribution is not restricted to the nucleus and that in certain cells, HMGB1 was also 
found in the cytoplasm [37]. It plays an important role in regulating cell migration, 
inflammation and metastasis. Wang et al. identified HMGB1 as a late mediator of 
endotoxin lethality in mice. These authors showed that monocytes/macrophages 
stimulated by lipopolysaccharide (LPS), tumour necrosis factor (TNF) or interleukin-1 
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(IL-1) secreted HMGB1 as a delayed response. In mice, injection of HMGB1 caused 
toxic shock whereas administration of anti-HMGB1 antibodies attenuated LPS-induced 
endotoxemia [38]. Sepsis is a systemic inflammatory response to bacterial products that 
can lead to multiple organ failure and death. Septic patients have shown increased serum 
level of HMGB1, which correlates with the severity of the infection. HMGB1 has also 
been shown to cause acute lung inflammation when administered intratracheally. 
Antibodies against HMGB1 decreased lung edema and neutrophile migration, whereas 
they did not reduce the levels of the other proinflammatory cytokines TNF-α, IL-1β or 
macrophage inflammatory protein-2 (MIP2). HMGB1 also participates in the regulation 
of neuroendocrine and immune responses to inflammatory processes [39]. Extracellular 
HMGB1 protein interacts with the extracellular matrix and the surrounding tissues and 
with several cell surface receptors, including the receptor for advanced glycation end 
products (RAGE) [40]. Necrosis is organ deterioration, whereas apoptosis is important 
for organ maintenance and differentiation. HMGB1 serves as a signal that determines 
whether cell death and injury will lead to necrosis or continue along a preintiated 
apoptotic pathway [35].  
Regulated Expression and Subcellular Localization of HMGB1 
 In transformed cell lines, HMGB1 is highly expressed at 106 molecules per cell, 
which is 10 times less than histones. However, in intact organs, its expression is 
developmentally regulated and/or responds to cues from the environment displaying an 
amazing variation in expression pattern, level of expression, and subcellular location. The 
HMGB1 gene is transcriptionally controlled by steroid hormones, using various signaling 
pathways including the cytokine-activated JAK/STAT pathway [41]. It is also likely that 
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other expression control, such as post-transcriptional controls of mRNA stability or 
translation, and protein stability exist. Studies by Mosevitsky et al. looked at distribution 
of HMGB1 in different mammalian tissues and found that lymphoid tissues and testis had 
high HMGB1 levels in both nuclei and cytoplasm whereas brain and liver had low levels, 
mainly in the cytosol [42]. These authors suggested that [HMGB1] is low in 
differentiated cells, and high in undifferentiated cells. In intact mice, HMGB1 expression 
is tightly regulated in the central nervous system [43, 44, 45]. In tumour cells, HMGB1 
protein is found in higher level than in normal tissue of counterpart cells [46, 47]. 
HMGB2 and HMGB3, which are structurally similar to HMGB1, have similar 
biochemical properties, but have a different expression pattern. These proteins are highly 
expressed in the embryo, and both are expressed at very low levels in the adults [48, 49]. 
Hmgb2-/- mice are viable, and only show a marked reduction in spermatogenesis [41]. 
Hmgb3 knock-outs have not been described yet.  
S.  cerevisiae HMG-Box Proteins 
 S. cerevisiae contains ten HMG-box proteins, including the HMGB1/2 homologs 
NHP6A/B, ~10 kDa proteins with a single HMG box, which have been shown to 
participate in the RNA polymerase II and III transcription systems [50-53]. HMO1 and 
HMO2 are ~25 kDa HMG-box proteins, also identified by homology-based motif-
prediction programs as having only a single HMG-box, in a position corresponding to the 
HMG box B of mammalian HMGB. However, HMO1 also contains an N-terminal box A 
domain with weak similarity to consensus HMG-box domains. The relative abundance of 
NHP6A/B and HMO1/2 was recently determined as part of a global analysis of protein 
expression in yeast. All four proteins are moderately abundant, with an estimated 1.9 x 
 12
104 molecules of HMO1 per cell compared to ~4 x 103 for NHP6A/B and 1.8 x 103 for 
HMO2 [54]. Strains bearing HMO1 or HMO2 mutant alleles are viable, although HMO1 
mutant strains have growth defects, compromised plasmid maintenance and nuclease 
sensitive chromatin, suggesting that HMO1 may play a role in stability of the chromatin 
structure [55]. HMO1 has been shown to interact genetically and physically with 
FKBP12 prolyl isomerase, a ubiquitous, highly conserved, abundant enzyme that 
catalyzes a rate-limiting step in protein folding. Dolinski and Heitman [56] found that 
mutations in HMO1 and in the FPR1 gene that encodes FKBP12 are synthetically lethal. 
A recent study implicates HMO1 as part of the rRNA transcription apparatus, where it 
was proposed to function in a similar capacity as the Upstream Binding Factor (UBF), 
which is an auxiliary factor in the mammalian and amphibian RNA Polymerase I 
transcription systems; UBF has six HMG domains [57]. HMO1 has also recently been 
shown to participate in mutagenesis control, but its exact role remains to be elucidated. 
 The C terminus of HMO1 has a long run of basic residues not found in any other 
HMGB1/2 protein. In vivo, the C terminus is dispensible for function whereas HMG Box 
B is essential. As the basic C-terminus is predicted to harbor the nuclear localization 
signal, the implication of this observation is that the growth phenotype characteristic of 
the hmo1 knockout may be reversed by HMO1 mutant protein that is confined to the 
cytoplasm. Immuno-localization experiments have shown that full length HMO1 is 
present both in the nucleus and cytoplasm [55]. Although the biological significance of 
the presence of HMO1 in the cytoplasm has not been established, it may serve the same 
critical and diverse roles as does the extracellular HMGB1.  
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 We show here that the divergent box A domain does participate in direct DNA 
contacts, and that it contributes modest structure-specific DNA binding to HMO1, while 
box B confers most of the DNA binding affinity. Interestingly, unlike  many HMGB 
proteins that insert negative supercoils in the presence of topoisomerase I in topologically 
closed DNA [51, 55], HMO1 did not supercoil relaxed closed circular DNA. We have 
also shown that the HMO1 basic C-terminal tail participates in DNA binding, and that it 
reduces the stability of the protein. Phosphorylation of HMO1 by casein kinase II lowers 
its affinity for DNA, suggesting that HMO1 can be regulated by post-translational 
modification. In vivo studies showed that HMO2 knockout has a slower growth 
phenotype (contrary to a previous report [55]) which is only evident in the presence of an 
HMO1 knockout, indicative of an overlap in function of these proteins. Using green 
fluorescent protein (GFP), HMO1 was localized to the cytoplasm and the nucleus, while 
HMO1 with the C-terminal domain deleted (M210) was localized only to the cytoplasm. 
Previous studies [55] have shown that hmo1 knockouts transformed with the vector 
carrying the M210 gene fully recovers to show wild type phenotype.  This shows that the 
essential and unique function of HMO1 protein is in the cytoplasm and not in the nucleus.  
DNA Supercoiling by Vaccinia Topoisomerase I 
 DNA topoisomerases are ubiquitous enzymes that manage DNA topology in the 
cell. They participate in a variety of cellular processes by solving the DNA topological 
problems associated with replication, transcription, recombination, chromosome 
condensation, decatenation and unknotting of DNA (reviewed in [59, 60]). 
Topoisomerases fine-tune DNA topology to facilitate protein interactions with the DNA 
which can be negatively affected by too much or too little supercoling. They alter DNA 
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topology by the concerted cleavage and religation of DNA strand(s). The nucleophilic 
attack of an active-site tyrosine on a phosphodiester DNA bond generates a 
phosphotyrosyl linkage, providing a transient protein-linked gate through which another 
DNA strand or duplex may pass. A second transesterification resolves the tyrosyl-DNA 
linkage to restore DNA integrity [59, 60, 61]. 
 With the recognition that topoisomerases play an important role in controlling 
DNA topology, great interest has developed, especially due to the discovery of 
topoisomerase targeted compounds. Clinically important anticancer and antibacterial 
compounds that target topoisomerases are now in use. Camptothecin and its analogues 
have shown remarkable antitumor activity against pediatric and adult malignancies [62]. 
Fluoroquinolones are compounds that target topoisomerases and are in wide clinical use 
as antibacterial agents [63, 64, 65]. 
Classification of Topoisomerases 
 Topoisomerases are classified into subfamilies which are distinguished by 
common biochemical properties and similarity in structure. While DNA cleavage by all 
topoisomerases leads to formation of a transient covalent intermediate in which a tyrosine 
is linked to a broken DNA strand, type II topoisomerases cleave both strands, which 
results in DNA topoisomers differing in linking number in steps of two. They are further 
divided into two different subfamilies based on structural considerations; type IIA and 
IIB subfamilies. Type I topoisomerases relax supercoiled DNA, but unlike type II 
topoisomerases, type I enzymes cleave only one strand and the linking number changes in 
steps of one. They are also further classified as either type IA, if the protein link is to a 5′ 
phosphate or type IB, which form a covalent bond to a 3'-phosphate. Type I 
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topoisomerases are found in all eukaryotes, where they relax both positive and negative 
supercoils [59, 60, 61]. 
Cellular Roles of DNA Topoisomerases 
 Escherichia coli has four DNA topoisomerases, two type IA (DNA 
topoisomerases I and III) and two type IIA enzymes (DNA gyrase and DNA 
topoisomerase IV). Genetically, functional overlap of each enzyme has been shown 
however, it appears that each enzyme has been optimized to carry out its own particular 
set of topological manipulations. DNA gyrase is the only known topoisomerase that 
generates negative supercoils by use of ATP as the energy source. As such, DNA gyrase 
plays an important role in chromosome condensation leading to proper chromosome 
partitioning at cell division [66, 67]. Any positive supercoils that are generated in the cell 
during processes like transcription or replication are resolved by DNA gyrase. 
Topoisomerase IV plays important roles in decatenation during replication [68] as well as 
relaxing negative supercoils in the cell [69], along with topoisomerase I [70] to prevent 
excessive negative supercoils generated by DNA gyrase or any other cellular processes 
like transcription and replication. 
 In S. cerevisiae and Schizosaccharomyces pombe, topoisomerase I (IB subfamily) 
is dispensable for growth, but topoisomerase IIA is required to decatenate linked 
chromosomes and prepare them for segregation at mitosis [71, 72]. Topoisomerase II 
relaxes supercoils of both signs and as such, it substitutes for topoisomerase I in its 
absence. Deletion of topoisomerase III (type IA subfamily) in S. cerevisiae results in 
slow growth exhibited by elevated levels of mitotic recombination. This deletion also 
results in sporulation failure due to a defect in meiotic recombination [73, 74]. 
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 In higher eukaryotes, topoisomerase I is indispensable during development and 
during cell division [75, 76]. Higher eukaryotes contain two isoforms of topoisomerase II 
and III termed α and β [59].  
General Features of Type IA DNA Topoisomerase I  
With the exception of the Methanopyrus kandleri encoded topoisomerase, all type IA 
topoisomerases are monomeric, and they require Mg(II) for the DNA relaxation activity. 
These proteins relax only negative  supercoils, but the relaxation does not go to 
completion and they require an exposed single-stranded region within the substrate DNA 
[59, 77]. These enzymes have been shown to catalyze the knotting, unknotting, and 
interlinking of single-stranded circles as well as the knotting, unknotting, catenation, and 
decatenation of gapped or nicked duplex DNA circles (reviewed in [59]). Although 
considerable sequence diversity is observed in the type IA subfamily, E. coli 
topoisomerase I, a prototype of this subfamily that is well studied, represents some 
common features. The core cleavage/strand passage domain that is found at the N-
terminal contains the active site tyrosine.   Expression of this N-terminal fragment yields 
a protein that retains the ability to cleave a single-stranded oligonucleotide, but is unable 
to relax plasmid DNA [78]. This catalytic domain is followed by a Zn(II)-binding 
domain. Although dispensable for activity in vitro, the C-terminal domain is rich in basic 
amino acids and contributes to substrate binding with preference for a single-stranded 
DNA [79, 80, 81]. In comparison to other type IA topoisomerases, both E. coli and S. 
cerevisiae topoisomerase III lack a Zn(II) binding domain. Conversely, human 
topoisomerase IIIα and IIIβ have a Zn(II) binding domain. It seems, however, that type 
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IA topoisomerases possess a relatively basic C-terminal domain that although not 
conserved, contributes to DNA binding.  
General Features of Type IB DNA Topoisomerase 
 The type IB subfamily of topoisomerases is made up of three classes which 
include eukaryotic topoisomerase I, poxvirus topoisomerase I and prokaryotic 
topoisomerase V from M. kandleri [82, 83]. These proteins share structural and 
functional properties with the tyrosine recombinases and some phage integrases [84]. 
Unlike type IA, type IB topoisomerases relax to completion  both positive and negative 
supercoils and as such, there is no need for exposed single-stranded region within the 
substrate DNA. Type IB contains no bound metal ions, and DNA relaxation does not 
require Mg(II). Human DNA topoisomerase I has four distinct domains; 1) the N-
terminal domain which has nuclear localization signals and sites for interaction with other 
proteins such as nucleolin and SV40, 2) the core domain which is highly conserved, binds 
DNA and contains most of the catalytic residues except for the active site tyrosine, 3) the 
linker domain which is poorly conserved and 4) the C-terminal domain which is 
conserved and contains the active site tyrosine. Human topoisomerase I is proposed to 
follow a “controlled rotation” mechanism for DNA relaxation, in which ionic interactions 
between DNA and protein regulate the DNA winding process [85, 86]. 
 The poxvirus topoisomerases are considerably smaller than cellular 
topoisomerases, are of fairly uniform size (314-333), and probably constitute the minimal 
functional unit of a type IB topoisomerase. Vaccinia topoisomerase I is a 314-amino acid 
protein that binds to duplex DNA with stringent specificity for transesterification at DNA 
sites containing the sequence 5'-(C/T)CCTT↓ [87-91]. The 3' phosphate of the incised 
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strand is linked to Tyr-274 of the enzyme. Vaccinia topoisomerase I consists of two 
structural domains joined through a trypsin-sensitive bridge. The N-terminal domain 
(amino-acids 1-80), which is highly conserved in poxvirus and vertebrate topoisomerases, 
contacts the-(C/T)CCTT DNA site in the major groove [92, 93]. The C-terminal domain 
(amino-acids 81-314) comprises an autonomous catalytic domain that performs the same 
repertoire of reactions as the full-sized topoisomerase I [94, 95]: relaxation of supercoiled 
DNA, site-specific DNA transesterification, and DNA strand transfer [94]. The structure 
of the catalytic domain is similar to that of human topoisomerase I except for a 
displacement of the active site tyrosine [71, 95]. The catalytic domain is also very similar 
to core domain III and a 19 amino acid region encompassing the active site of human 
topoisomerase I.  
Fluoroquinolone Compounds 
Since the first quinolone nalidixic acid was developed, the quinolones have 
undergone structural modifications, in particular the addition of a fluorine at position 6, 
to produce the fluoroquinolones (reviewed in [67]). This has seen their potency and 
pharmakokinetic profile greatly increase. Fluoroquinolones are topoisomerase II poisons 
known to target DNA gyrase and topoisomerase IV in bacterial cells [64, 65, 96]. The 
interaction of norfloxacin with the DNA-gyrase complex has been investigated in some 
detail. While binding of norfloxacin to gyrase was undetectable, it was shown to bind 
DNA directly and to exhibit a binding mode involving preferred recognition of single-
stranded DNA. Drug binding was enhanced by the presence of gyrase, suggesting that 
DNA-binding revealed a cryptic norfloxacin binding site on the enzyme [97, 98]. The 
nature of the norfloxacin-DNA complex has been analyzed by several groups, with 
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somewhat disparate conclusions. Norfloxacin was reported to require magnesium ions for 
DNA binding, with Mg2+ proposed to act as a bridge between the negatively charged 
DNA phosphates and the carbonyl and carboxyl moieties of norfloxacin [99]. However, 
more recent reports showed binding of norfloxacin to DNA in the absence of Mg2+ and 
suggested a mode of DNA interaction that ruled out classical DNA intercalation or 
groove binding, based in part on the observation that the molecular plane of norfloxacin 
is nearly perpendicular to the helix axis [100-101]. These authors also found that DNA 
unwinding by norfloxacin is negligible and proposed instead that the compound may 
induce a bend in the DNA helix.  
 The inhibitory effect of fluoroquinolones is based on their ability to stimulate the 
forward rate of the topoisomerase II-mediated DNA scission; after binding the cleavable 
complex, the fluoroquinolone induces a conformational change in the enzyme that 
prevents religation [102-104]. The replication fork is blocked by the stabilization of these 
complexes, resulting in irreversible DNA-enzyme complexes, which probably leads to 
lethal release of double-stranded DNA breaks [63, 64, 105, 106]. 
 The fluoroquinolone derivative ofloxacin was previously shown also to exhibit 
antiviral activity against Vaccinia virus, and the inhibitory activity shown to correlate 
with inhibition of topoisomerase I purified from Vaccinia virus cores [107]. Therefore, 
with wider screening of these fluoroquinolone compounds, it is likely to result in 
discovery of compounds with antiviral activity or compounds that can be optimized or act 
as a lead to more potent antiviral agents.  
 Here we describe a novel interaction of enrofloxacin with Vaccinia topoisomerase 
I in vitro. Enrofloxacin, a fluoroquinolone antibiotic which targets DNA gyrase and 
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topoisomerase IV in bacterial cells inhibits DNA relaxation by Vaccinia topoisomerase I 
in a concentration dependent fashion. In the presence of relaxed DNA, however, 
enrofloxacin causes Vaccinia topoisomerase I to supercoil DNA, reversing its action as a 
DNA relaxing enzyme. Further characterization indicates that enrofloxacin does not 
interfere with the initial strand scission by Vaccinia topoisomerase I, nor does it interfere 
with enzyme’s ability to bind DNA. The mechanism with which Vaccinia topoisomerase 
I supercoils relaxed DNA, an energetically unfavorable, yet ATP-independent process, 
must entail protein-DNA contacts downstream of the cleavage site, as opposed to the free 
rotation mechanism proposed for DNA relaxation. In cell culture, enrofloxacin and 
several other fluoroquinolone compounds inhibited Vaccinia virus.  
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CHAPTER 2 
 
THE SACCHAROMYCES CEREVISIAE HIGH MOBILITY GROUP BOX 
PROTEIN HMO1 CONTAINS TWO FUNCTIONAL DNA BINDING DOMAINS  
  
Introduction 
 
 High-mobility group (HMG) proteins constitute a significant proportion of non-
histone proteins of eukaryotic chromatin. They are abundant proteins that are grouped 
into three major classes, in part based on their DNA-binding characteristics: HMGA, 
HMGB, and HMGN [1-4]. HMGB proteins contain one or more homologous repeats of 
the ~80-amino acid sequence HMG box and are classified into two families based on the 
abundance, function and DNA specificity of this conserved region [1, 5, 6]. The 
moderately sequence-specific family is typified by transcription factors such as sex-
determining factor SRY and lymphoid enhancer factor LEF-1 [7, 8], while the non-
sequence-specific family is represented by so-called architectural factors HMGB1/2 and 
the Saccharomyces cerevisiae non-histone chromosomal proteins 6A and 6B (NHP6A/B) 
[9].  
 The tertiary structures of HMG boxes from sequence-specific and non-sequence-
specific proteins have revealed an evolutionarily conserved, common global fold 
consisting of an L-shaped structure composed of three α-helices [10-19]. The HMG DNA 
binding domain, which interacts with ~10 bp of duplex, binds to the minor grove of DNA 
by partial intercalation of one or two surface-exposed, conserved hydrophobic residues 
into the base pair stack. Consequently, the DNA is greatly distorted, resulting in a sharp 
bend and helical underwinding [4, 8, 14, 16, 20]. SRY and LEF-1 cause bending by 
insertion of helix I hydrophobic residues Ile and Met, respectively, into the base pair  
Reprinted from Journal of Biological Chemistry vol 279. Copyright 2004, The American Society for 
Biochemistry and Molecular Biology, Inc 
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Figure 2.1 Alignment of HMG-box helices I and II. For non-sequence specific proteins, 
box A and box B of rat HMGB1 is shown along with S. cerevisiae NHP6A, Drosophila 
melanogaster HMGD and S. cerevisiae HMO1. The HMO1 box B insertion is indicated 
in lower case. Sequence specific proteins are human SRY, mouse LEF-1 and Xenopus 
laevis UBF box A. Residues corresponding to positions 16 and 37 of HMGB1 helices I 
and II, respectively, are in bold. 
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stack (Figure 1[ 8, 17]). HMGB1 contains tandem HMG box domains referred to as box 
A and box B; DNA-intercalating residues are located at positions 16 and 37 of helices I 
and II, respectively, and both can contribute to binding affinity [11, 13, 16, 19]. HMGB 
proteins recognize DNA with structural specificity, binding preferentially to distorted 
DNA such as 4-way junctions, mini-circles, and cisplatinated DNA, and they supercoil 
relaxed, topologically closed DNA in the presence of topoisomerase I [11, 16, 20-25]. 
HMGB proteins have been implicated in diverse biological processes such as 
transcription, recombination, replication and DNA repair by virtue of their ability to 
facilitate assembly of nucleoprotein complexes [1, 3, 5]. 
 S. cerevisiae contains ten HMG-box proteins, including the HMGB1/2 homologs 
NHP6A/B, ~10 kDa proteins with a single HMG box, which have been shown to 
participate in the RNA polymerase II and III transcription systems [9, 26-28]. HMO1 and 
HMO2 are ~25 kDa HMG-box proteins, also identified by homology-based motif-
prediction programs as having a only single HMG-box, in a position corresponding to 
box B of mammalian HMGB. However, HMO1 also contains an N-terminal box A 
domain with weak similarity to consensus HMG-box domains (Figure 1). The relative 
abundance of NHP6A/B and HMO1/2 was recently determined as part of a global 
analysis of protein expression in yeast. All four proteins are moderately abundant, with 
an estimated 1.9 x 104 molecules of HMO1 per cell compared to ~4 x 103 for NHP6A/B 
and 1.8 x 103 for HMO2 [29]. Strains bearing HMO1 or HMO2 mutant alleles are viable, 
although HMO1 mutant strains have growth defects, compromised plasmid maintenance 
and nuclease sensitive chromatin, suggesting that HMO1 may play a role in stability of 
the chromatin structure [30]. HMO1 has been shown to interact genetically and 
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physically with FKBP12 prolyl isomerase, a ubiquitous, highly conserved, abundant 
enzyme that catalyzes a rate-limiting step in protein folding. These authors found that 
mutations in HMO1 and in the FPR1 gene that encodes FKBP12 are synthetically lethal 
[31]. A recent study implicates HMO1 as part of the rRNA transcription apparatus, where 
it was proposed to function in a similar capacity as the Upstream Binding Factor (UBF), 
which is an auxiliary factor in the mammalian and amphibian RNA Polymerase I 
transcription systems; UBF has six HMG domains [32]. HMO1 has also recently been 
shown to participate in mutagenesis control, but its exact role remains to be elucidated 
[33].  
 We show here that the divergent box A domain does participate in direct DNA 
contacts, and that it contributes modest structure-specific DNA binding to HMO1, while 
box B confers most of the DNA binding affinity. HMO1 displays a longer residence time 
on constrained DNA minicircles, consistent with its role in the maintenance of chromatin 
structure.  
Experimental Procedures 
Cloning and Purification of Proteins 
 The gene encoding HMO1 was amplified from yeast genomic DNA using primers 
modified to introduce NdeI sites at both ends of the PCR product; forward primer, 5′-
GCCTGTCACCATATGACTACAG-3′, reverse primer, 5′- 
AGTAACGCATATGTCCGTCC-3′ (NdeI sites underlined). The HMO1 gene was 
cloned into the NdeI site of plasmid pET5a, and plasmid carrying the HMO1 gene was 
transformed into E. coli BL21(DE3)pLysS. HMO1 expression was induced by addition 
of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at an OD600 of 0.4 and the culture 
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incubated for 3 h. Cells were pelleted and resuspended in lysis buffer (50 mM Tris-HCl 
pH 8.0, 1 M NaCl, 5% glycerol, 5 mM EDTA, 1 mM 2-mercaptoethanol, 1 mM phenyl 
methyl sulfonyl fluoride (PMSF)). Cells were disrupted by sonication and nucleic acids 
digested by addition of DNase I followed by a one-hour incubation on ice. The extract 
was clarified by centrifugation at 5000 × g for 20 min. The supernatant was dialyzed 
overnight against HA buffer pH 8.7 (20 mM Tris-HCL, 50 mM KCl, 10% glycerol, 1 
mM EDTA, 4 mM 2-mercaptoethanol, and 1 mM PMSF). The dialysate was passed 
through tandem columns of DEAE-cellulose and CM-sepharose equilibrated with the 
same buffer. Proteins were eluted with a 120 ml linear gradient from 50 mM KCl (HA 
buffer) to 1 M KCl (HB buffer; 20 mM Tris-HCl, 1 M KCl, 10% glycerol, 1 mM EDTA, 
4 mM 2-mercaptoethanol, 1 mM PMSF). Peak fractions were collected, dialyzed 
overnight in HA buffer pH 8.7, and passed through a Heparin column equilibrated with 
the same buffer and proteins were eluted and analyzed as described above. Peak fractions 
were collected and dialyzed overnight in HA buffer pH 7.0. The dialysate was passed 
through CM-sepharose equilibrated with the same buffer and proteins were eluted and 
analyzed as described above. Pure HMO1 fractions were concentrated and quantitated on 
Coomassie Blue stained SDS-PAGE gels using BSA as a standard.  
 The gene encoding HMO1 was also subcloned into pET28b for expression with 
an N-terminal His6-tag. Using a PCR-based site-directed mutagenesis approach, a stop 
codon was inserted into the HMO1 gene in place of Pro91 to create the truncated protein 
HMO1-BoxA, lacking box B and the basic tail region, using primers forward, 5'-
CGCTGCTTGAGTCAAGGCT-3', and reverse, 5'-
ATAATAGCATCTTTATCATCATCAATAGGG-3'. Plasmids, HMO1-pET28b and 
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BoxA-pET28b, were transformed into E. coli Rosetta Blue. Cultures were grown to an 
OD600 of 0.2 and expression was induced with 1mM IPTG for 3 h.  Cells were pelleted, 
resuspended in a dialysis/lysis buffer pH 7 (50 mM NaxHyPO4, 300 mM NaCl, 10 mM 
imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF), disrupted by 
sonication, and nucleic acids digested by addition of DNase I followed by a one-hour 
incubation on ice. The lysate was dialyzed overnight in dialysis/lysis buffer. The 
dialysate was passed through a Ni-NTA column equilibrated with dialysis/lysis buffer 
and washed with 5 column volumes of wash buffer pH 7 (50 mM NaxHyPO4, 300 mM 
NaCl, 20 mM imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF). 
Proteins were eluted with a 50 ml linear gradient from 20 mM imidazole (wash buffer) to 
250 mM imidazole (elution buffer: 50 mM NaxHyPO4, 300 mM NaCl, 250 mM 
imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF) followed by 100 
ml of elution buffer. Pure HMO1 and HMO1-BoxA fractions were quantitated on 
Coomassie Blue stained SDS-PAGE gels using BSA as a standard. Bacillus subtilis HU 
was cloned from B. subtilis genomic DNA and overexpressed in E. coli. Detailed 
procedures for its cloning and purification will be reported elsewhere. 
Circular Dichroism Spectroscopy 
 CD spectra were recorded on an AVIV Model 202 CD spectrophotometer using a 
1 cm pathlength sample cell. Wavelength scans from 200 nm to 240 nm were performed 
in triplicate, and data points were averaged and smoothed using standard methods. The 
wavelength scan for His6-tagged HMO1 was recorded at 25ºC, with a protein 
concentration of 0.025 mg/ml in 2.5 mM NaxHyPO4, pH 7.0, 0.5% glycerol, 10 mM 
NaCl. The wavelength scan for His6-tagged HMO1-BoxA was recorded at 4ºC, using a 
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protein concentration of 0.05 mg/ml in 1 mM Tris, pH 7.0, 0.03% Tween 20, 10% 
glycerol, 2.8 mM KCl.   
Ligase-Mediated Circularization 
  Ligation substrates were prepared by digestion of PCR amplified or plasmid 
DNA with appropriate endonucleases. pET5a was digested with BamHI and BgIII to 
generate a 136 bp fragment while BspHI digestion generated a 105 bp fragment. An 87 
bp fragment was generated by digestion of pcDNA3 with SacI. A 75 bp DNA fragment 
was generated by PCR amplification of the 390-538 bp region of pUC18 using Taq 
polymerase and primers 5′-GCCAGTGCCAAGCTTGCATG-3' and 5′-
CTTTATGCTCTCGAGTCGTATGTT-3′, followed by digestion with SacI. DNA 
fragments were purified on 7% (w/v) polyacrylamide gels and 5'-end labeled with T4 
polynucleotide kinase and ( -32P) ATP. Reactions were initiated by addition of 20 units 
of T4 DNA ligase to a final volume of 100 µl reaction buffer (20 mM Tris-HCl pH 8, 50 
mM NaCl, 10 mM MgCl2, 0.1 mM Na2EDTA, 1 mM DTT, 0.05% BRIJ58) containing 
1200 fmol DNA, with or without HMO1. Time points were taken over 90 minutes. For 
each time point, 8 µl of the reaction mixture was quenched by addition of 5 µl stop buffer 
(75 mM EDTA, 15% glycerol, 0.1%bromophenol blue (BPB), 0.1%xylene cyanol, 6 
µg/µl proteinase K). Samples were heated at 55°C for 15 minutes and resolved on prerun 
7% (w/v) native polyacrylamide gels (39:1 acrylamide:bisacrylamide) gels at 4°C with 
0.5X TBE (50 mM Tris-borate, 1 mM EDTA). Quantitation was performed on a 
Molecular Dynamics Storm Phosphorimager using software supplied by the 
manufacturer.  
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DNA Supercoiling  
 Reactions contained 0.2 µg relaxed closed circular pUC18 plasmid, prepared by 
adding 2.5 units of Vaccinia topoisomerase I (Epicenter) to supercoiled pUC18 in 50 mM 
Tris, pH 7.5, 2.5 mM MgCl2, 100 mM NaCl and 0.1 mM EDTA. After 1.5 h at 37°C, 
varying amounts of HMO1 were added and the reactions incubated for 1 h at 37°C. 
Reactions were quenched with 5 µl termination buffer (5X TBE, 5% SDS, 15% sucrose, 
0.1%BPB, 0.1%xylene cyanol, 2 µg/µl proteinase K) and incubated for 1 h at 37°C. 
Samples were loaded on 1% 1X TBE agarose gels and electrophoresed at 2 V/cm for 12 h 
in 1X TBE buffer.  
Agarose Gel Retardation 
 Reactions were incubated at room temperature in 10 µl reaction buffer containing 
0.2 µg linear, relaxed closed circular or supercoiled pUC18 and varying amounts of 
HMO1 or HMO1-BoxA. Complexes were resolved on 0.7% 1X TAE agarose gels and 
electrophoresed at 2.5 V/cm for 3 h in 1X TAE buffer (40 mM Tris-acetate, 1 mM 
EDTA, pH 8.0). Gels were stained with ethidium bromide after electrophoresis. 
Electrophoretic Mobility Shift Assays (EMSA) with DNA minicircles 
 The 105 bp fragment generated by BspHI digestion of pET5a DNA was 5'-end 
labeled with T4 polynucleotide kinase and ( -32P) ATP. DNA minicircles were generated 
by intramolecular ligation of the 32P-labeled 105 bp DNA fragment with 20 units of T4 
DNA ligase in the presence of Thermotoga maritima HU for 2 h at room temperature 
(34). Samples were treated with Exonuclease III for 1 h at room temperature and the 
reactions quenched with stop buffer. The de-proteinised DNA was purified on a 6% (w/v) 
native polyacrylamide gel (39:1 acrylamide:bisacrylamide).  
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 EMSA was performed with linear and circular 105 bp DNA. Reactions were 
incubated at room temperature in 10 µl reaction buffer containing 5 fmol DNA and 
varying amounts of HMO1. Where indicated, reactions were performed in the absence of 
MgCl2. Samples were resolved on prerun 7% (w/v) native polyacrylamide gels (39:1 
acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE running buffer. Complexes were 
visualized by phosphorimaging. In DNA competition assays, 10 fmol of 32P-labeled 
linear or circular 105 bp DNA was incubated with HMO1 for 30 min at room temperature 
to allow complex formation, followed by addition of varying amounts of linear pUC18 
plasmid DNA. Samples were resolved as described above. For calculating fractional 
complex formation, the region on the gel from the slowest migrating complex to the free 
DNA was considered as complex. 
EMSA with Four-Way DNA Junctions 
 Four-way junctions were constructed using a published protocol [35]; the 
sequence of individual strands was as described [36]. The 4-way junction was prepared 
by annealing the four strands, followed by purification of the junctions on native 
polyacrylamide gels. To ensure that all oligonucleotides were present, aliquots of the 
purified junctions were run on denaturing gels. EMSA were performed as described 
above with 5 fmol DNA and varying amounts of HMO1 or HMO1-BoxA; for 
experiments with HMO1-BoxA, the reaction buffer was modified to contain only 25 mM 
NaCl, MgCl2 was omitted, and 0.5% Tween 20 was included. In competition assays, 20 
or 1000-fold mass excess of unlabeled linear pUC18 DNA was added after the addition 
of HMO1. Complexes were resolved and quantified as described above.  
 36
EMSA with linear duplex DNA and DNA Containing Loops, Nicks, Gaps or Overhang 
 Oligonucleotides were purchased and purified by denaturing gel electrophoresis. 
Oligonucleotides used to generate constructs with loops, nicks, gaps or overhangs 
included a common 37 nt top strand: 5′-
CCTAGGCTACACCTACTCTTTGTAAGAATTAAGCTTC-3′. To generate 37 bp 
duplex DNA, complementary oligonucleotides were mixed at equimolar concentrations, 
heated at 90° C, and slowly cooled to room temperature. To generate looped DNA, a 
complementary strand with a pair of 2-nt mismatches with 11 nt spacing (3′-
GGATCCGATGCCATGAGAAACATAGTTAATTCGAAG-5′, with mismatched 
nucleotides indicated in bold) was annealed to the top strand. A spacing of 11 bp was 
chosen as it represents the spacing that yielded optimal complex formation with 
mammalian HMGB1 [37]. The 37 bp DNA with a central nick, gap, or a 3'-overhang 
were prepared as described [36]. The 18 bp duplex corresponded to the sequence of the 5' 
half of the 37 bp duplex. The sequence of the 26 bp duplex was: 5'-
CGTGACTACTGTAAGTCGATGATCCG-3'. EMSA were performed as described 
above with 5 fmol DNA. The observed fraction of complex formation was corrected for 
dissociation during electrophoresis, and binding isotherms for HMO1 binding to 26 bp 
DNA was fitted as described [36]. All experiments were done at least in triplicate, and 
values are reported as the mean ± standard deviation. 
 Competition assays involving HMO1-BoxA were performed with 32P-labeled 26 
bp DNA. Reactions were incubated at room temperature in 10 µL reaction buffer 
containing 10 fmol of DNA, 400 fmol B. subtilis HU or 4 pmol full-length HMO1, and 
varying amounts of HMO1-BoxA.  B. subtilis HU or HMO1 was incubated with DNA at 
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room temperature for 5 min, followed by addition of HMO1-BoxA. Samples were 
resolved on prerun 7% native gels at 4°C with 0.5X TBE running buffer. Complexes 
were visualized by phosphorimaging. 
Results 
DNA binding by HMO1 and HMO1-BoxA 
 Recombinant HMO1 and His6-HMO1 were purified to apparent homogeneity, as 
judged by Coomassie Blue-staining of SDS-PAGE gels. For analysis of DNA binding by 
the divergent box A domain, N-terminally His6-tagged HMO1-BoxA was also prepared 
(Figure 2.2A). CD spectra of both full-length HMO1 and HMO1-BoxA are characterized 
by negative ellipticities at 208 and 222 nm, indicative of significant α-helical content 
(Figure 2.2B-C). The qualitatively comparable spectra suggest that HMO1-BoxA is an 
independently folded domain. The previously reported ability of HMO1 to self-associate 
[31], evident at higher protein concentrations, was also characteristic of the box A 
domain for which well-resolved CD spectra required the presence of detergent. 
 DNA binding was analyzed with Electrophoretic Mobility Shift Assays (EMSA). 
While no stable complex could be seen on incubation of 18 bp DNA with full-length 
HMO1 (data shown), a single complex formed with 26 bp DNA (Figure 2.3). No 
difference was seen between N-terminally His6-tagged and untagged HMO1 (data not 
shown; all subsequent experiments were performed with untagged HMO1). The apparent 
dissociation constant Kd for HMO1 binding to 26 bp DNA is 39.5 ± 5.0 nM. HMO1 
forms two complexes with 37 bp DNA (Figure 2.4A), as seen previously with the 
mammalian two-HMG box protein HMGB1 [37], suggesting similar site sizes. Half-
maximal saturation is observed at 33.1±3.9 nM HMO1. For reactions performed in the  
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Figure 2.2 HMO1 and HMO1-BoxA have significant α-helical content.  (A) SDS-
PAGE gels showing purified His6-HMO1 (left) and His6-HMO1-BoxA (right). (B)-(C) 
CD spectra of HMO1 and HMO1-BoxA, respectively. 
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Figure 2.3 Electrophoretic analysis of 26 bp DNA titrated with HMO1. (A) Reactions 
contain 5 fmol DNA. Reactions in lanes 2-14 contain 6, 12, 24, 48, 72, 96, 120, 144, 188, 
192, 216, 240, and 264 nM HMO1. (B) Binding isotherm for HMO1 binding to 26 bp 
DNA. When error bars are not shown, they are smaller than the symbol size. Inset shows 
purified untagged HMO1 (lane 2). Molecular weight markers are identified at the left (in 
kDa). 
 
 
 
 
 
 
 
 40
 
 
Figure 2.4 Binding of HMO1 and B. subtilis HU to 4-way junctions and linear duplex 
DNA. (A) HMO1, (B) B. subtilis HU. Reactions contain 5 fmol DNA, and protein 
concentrations are 0, 1, 2, 4, 8, 16, 24, 28, 32, 36, 40 and 60 nM (identical for all panels). 
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absence of Mg2+, the affinity is slightly higher with half-maximal saturation of 15.6±2.3 
nM (data not shown). The lower affinity measured in the presence of magnesium ions 
may not be due to effects caused specifically by the divalent ions, but a general effect of 
raised ionic strength.  
 While no complex is detected upon incubation of 26 bp DNA with HMO1-BoxA, 
a competition experiment in which full-length HMO1 is incubated with 26 bp DNA in the 
presence of increasing concentrations of HMO1-BoxA shows a reduction in HMO1-DNA 
complex formation, suggesting that HMO1-BoxA competes for binding to the DNA (data 
not shown). However, since HMO1-BoxA self-associates, this experiment does not 
exclude the possibility that HMO1-DNA complex formation is impaired due to 
interactions between HMO1-BoxA and full-length protein. The competition experiment 
was therefore also performed using the unrelated architectural protein HU from Bacillus 
subtilis (Figure 2.5A). Consistent with DNA binding by HMO1-BoxA, HU-DNA 
complex formation is also reduced in the presence of HMO1-BoxA. Efficient competition 
requires µM concentration of HMO1-BoxA, suggesting low-affinity binding, consistent 
with HMO1-BoxA complexes with 26 bp DNA being too unstable to detect following 
electrophoresis. 
HMO1 and HMO1-BoxA have only limited preference for distorted DNA 
 HMGB proteins have been shown to recognize distorted DNA structures 
selectively [21, 24, 35, 37, 38]. Compared to linear duplex DNA, however, HMO1 did 
not show binding preference for DNA with loops, nicks, gaps or overhangs (data not 
shown); by comparison, the 37 bp looped DNA construct served as a preferred substrate 
for mammalian HMGB1 [37]. Evidently, intrinsic DNA flexibility does not confer a  
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Figure 2.5 HMO1-BoxA binds DNA. (A) HMO1-BoxA competes with B. subtilis HU 
for binding to 26 bp DNA. Reactions contain 10 fmol DNA and 50 nM HU (lanes 2-8). 
Reactions in lanes 3-8 contain 0.2, 0.4, 0.9, 8.8, 17.6, and 26.4 µM HMO1-BoxA. (B) 
Electrophoretic analysis of HMO1-BoxA binding to 4-way junction DNA (5 fmol). 
Reactions in lanes 2-7 contain 2.2, 11, 22, 33, 44, and 66 µM HMO1-BoxA. 
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significant energetic advantage for HMO1 to bind DNA. Surprisingly, HMO1 also had 
only limited preference for 4-way junctions (Figure 2.4A). Half-maximal saturation is 
observed at 19.6±2.2 nM of HMO1 and for reactions performed in the absence of Mg2+, 
half-maximal saturation is 6.1±1.1 nM. This is in distinct contrast to other HMGB 
proteins which were shown to bind 4-way junction DNA only in the open square 
conformation that is preferred in the absence of Mg2+ [39]. For comparison, B. subtilis 
HU showed the expected preference for the 4-way junctions compared to linear DNA 
with a sequence that corresponds to the longest arms of the 4-way junctions, confirming 
integrity of the 4-way junction construct (Figure 2.4B). As shown in Figure 5B, HMO1-
BoxA also exhibits a modest preference for 4-way junction DNA; consistent with self-
association of HMO1-BoxA, stable complex formation is enhanced by the presence of 
detergent. Notably, the formation of detectable complexes with a migration pattern 
similar to that seen for full-length HMO1 confirms the ability of HMO1-BoxA to engage 
DNA directly. 
 When HMO1 was added to reaction mixtures containing both 4-way junction and 
linear duplex DNA, HMO1 bound with only modest preference to the 4-way junctions 
(Figure 2.6). In competition assays, EMSA was performed with either 32P-labeled 4-way 
junctions or 32P-labeled linear duplex DNA in the presence of unlabeled competitor linear 
or supercoiled plasmid DNA. HMO1 was competed off the linear and 4–way junction 
DNA equally efficiently by linear and supercoiled plasmid DNA (data not shown). These 
assays indicate that HMO1 does not have significant preference for supercoiled compared 
to linear plasmid DNA. To investigate the interaction of HMO1 with different DNA 
topologies further, agarose gel retardation assays were performed with negatively  
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Figure 2.6 HMO1 has only modest preference for 4-way junction DNA. Reactions 
contain linear duplex DNA and 4-way junctions. HMO1 was added at increasing 
concentrations, ranging from 10 nM to 120 nM. 
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supercoiled, relaxed and linear pUC18 plasmid. As shown in Figure 2.7, HMO1 has only 
modest preference for supercoiled DNA. Regardless of DNA topology, HMO1 causes the 
entire population of DNA to shift as a rather broad band, suggesting that HMO1 binds 
without cooperativity. Consistent with its low-affinity binding to 26 bp DNA, HMO1-
BoxA does not form complexes with plasmid DNA that are detectable following 
electrophoresis (data not shown). 
HMO1 exhibits a longer residence time on DNA minicircles  
  DNA mini-circles are circularized DNA shorter than the persistence length of 
∼150 bp. Since the DNA is highly constrained, a diminished need for DNA distortion 
may lower the free energy of interaction. HMO1 bound 105 bp circular DNA comparably 
to 105 bp linear DNA (Figure 2.8A). However, in DNA competition assays with linear 
pUC18 plasmid, HMO1 was more efficiently competed off linear 105 bp DNA; at 400-
fold excess plasmid DNA, HMO1 still bound 91% of the 105 bp circular DNA as 
opposed to only 13% of the linear 105 bp DNA (Figure 8B), suggesting a much longer 
residence time on the constrained minicircle. 
HMO1 bends DNA 
 Ligase-mediated circularization assays were performed in which the efficiency 
with which T4 DNA ligase mediates ring closure of DNA fragments that are shorter than 
the persistence length is measured [20, 40]. The ability of HMO1 to enhance ligase-
mediated DNA circularization was qualitatively assessed with 136, 105, 87, 75 and 65 bp 
duplex DNA. HMO1 facilitated formation of circles with DNA of 136, 105 and 87 bp, 
but not 75 or 65 bp (Figure 2.9).  
 46
 
 
Figure 2.7 Binding of HMO1 to supercoiled, relaxed and linear DNA. Lanes 1, 8 and 
15 with no HMO1 and lanes 2-7, 9-14 and 16-21 with increasing amounts of HMO1 
(1250 fmol-7500 fmol). Samples were analyzed on 0.7% agarose gels. 
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Figure 2.8 (A) Binding of HMO1 to linear and circular 105 bp DNA. EMSA with 10 
fmol DNA. Lanes 2-6 and 8-12 contain 2.5, 10, 25, 50, 75 nM HMO1 respectively. (B) 
DNA competition assay. HMO1 (5 pmol) was incubated with 10 fmol linear (left panel) 
or circular (right panel) 105 bp DNA and titrated with unlabeled linear pUC18 DNA. 
Lanes 3, 4, 5 and 8, 9, 10 contain 4, 40 and 400-fold excess of pUC18, respectively. 
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Figure 2.9 (A) Time-course ligation assay with 87 bp DNA. 100 fmol 87 bp linear 
DNA was incubated without (left panel) or with HMO1 (250 nM, right panel) up to 96 
minutes. Time points were taken at 6, 12, 24, 48, 72 and 96 min. Exonuclease III was 
added to reactions in lane 7 and 14 at 48 min time-points. Circular ligation products (lane 
14) were resistant to digestion by Exonuclease III. (B) Quantitation of ligation assays for 
136, 105 and 87 bp DNA. Effective concentrations of monomeric DNA differ for the 
three substrates, particularly for the 105 bp DNA for which formation of 210 bp dimer 
circles predominates. Initial rates therefore do not correlate with duplex length.   
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As expected, initial rates of cyclization are highest for the longer 136 bp DNA, however, 
the 87 bp DNA produced monomer circles most efficiently. Dimer circle formation and 
multimerization of the 87 bp DNA occurred in reactions with and without HMO1, 
although to a lesser extent compared to the other DNA constructs. The 105 bp DNA 
yielded the least efficient monomer circle formation, however, more than 50% of the 
DNA formed dimer circles even in the absence of the protein, lowering the effective 
concentration of monomeric DNA and causing the initial rate and net yield of monomer 
circles to be lower than that measured with 87 bp DNA. Secondly, the different cohesive 
termini of the DNA probes are recognized differentially by DNA ligase. By comparison, 
S. cerevisiae non-histone protein 6A (NHP6A) can form monomer circles with DNA 
substrates of 66 bp [20] while HMGB1/2 and HMG-D can form monomer circles with 
DNA substrates as short as 59 and 55 bp, respectively, at high protein concentrations [41, 
42]. The protein concentrations used in our experiments are comparable to the 
concentrations used for other HMGB proteins; our data therefore indicate that HMO1 
bends DNA, although not as effectively as other HMGB proteins.   
HMO1 does not supercoil relaxed DNA 
 Many HMGB proteins insert negative supercoils in the presence of topoisomerase 
I in topologically closed DNA [25, 30, 43]. To assess the ability of HMO1 to supercoil 
DNA, relaxed closed circular pUC18 DNA was incubated with increasing amounts of 
HMO1 (Figure 2.10). There was no evidence of DNA supercoiling by HMO1, nor did 
HMO1-BoxA supercoil DNA (not shown). This contrasts with a previous publication by 
Lu et al. who, focusing on analysis of HMO1 purified from yeast, reported that HMO1 
could indeed supercoil relaxed plasmid DNA [30].  
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Figure 2.10 HMO1 does not supercoil relaxed DNA. Lanes 1 and 2 contain supercoiled 
(S) and relaxed (R) pUC18 DNA, respectively. Increasing amounts of HMO1 (1250 
fmol-7500 fmol) in lanes 3-6 and Bsu HU (1250 fmol-7500 fmol) in lanes 7-10 were 
added to relaxed circular DNA. 
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Discussion 
 Recent studies have shown that the difference between sequence-specific HMGB 
proteins and the non-sequence specific homologs depends on individual DNA 
intercalating residues and the global features of the HMG box, which determines the 
mode of DNA recognition. For the tandem HMG boxes of HMGB1, the DNA 
intercalating residues are at positions 16 or 37, located in helices I and II respectively, 
and both can contribute to the binding affinity of the HMG boxes. Box A has an alanine 
at position 16, which does not intercalate with the DNA but forms a hydrophobic contact, 
whereas phenylalanine at position 37 is used as a bending wedge (Figure 2.1). Box B has 
a phenylalanine at position 16 and isoleucine at position 37, both of which are potential 
intercalating residues. Sequence-specific HMGB proteins have polar residues at position 
37, which participate in sequence-specific hydrogen-bond formation [8, 16, 42, 44]. For 
both box A and B of HMGB1, their ability to bend DNA is reflected in preferred binding 
to distorted DNA. Box B, with its two DNA-intercalating residues, introduces the 
greatest bend, whereas box A fails to bend DNA effectively [41, 45]. Box A has the 
greatest preference for distorted DNA due to stacking of the helix II bending wedge on an 
exposed base pair, whereas the affinity of box B for distorted DNA is only modestly 
greater than its affinity for duplex DNA [45, 46]. Accordingly, the presence of a 
hydrophobic DNA intercalating residue in position 16 of helix I appears to be important 
for bending, while a bending wedge in helix II may be required for selective recognition 
of distorted DNA.  
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 We have found HMO1 to bend DNA but to have only modest preference for 
distorted DNA structures, including the 4-way junction. The HMO1 box A domain is 
highly divergent from the consensus, containing a five amino acid insertion in the middle 
of helix III, including a helix-breaking glycine that is likely to affect its structure and 
mode of DNA interaction. However, our data show that the box A domain has significant 
α-helical content, consistent with an HMG-like fold, and that it is involved in direct DNA 
contacts (Figures 2.2 and 2.5). DNA bending by HMO1 would be consistent with the 
presence of hydrophobic residues in position 16 of both HMG boxes and the potential use 
of I37 of box A as an additional bending wedge. The limited preference of HMO1 for 
distorted DNA, combined with the low-affinity binding of HMO1-BoxA that is also only 
modestly enhanced by the presence of pre-bent DNA conformations, suggests that box A 
contributes the modest structure-specificity, while box B, which has no hydrophobic 
residue at position 37, confers most of the DNA binding affinity. The contribution of box 
A to DNA interactions is also consistent with the occluded site size for HMO1, which 
fails to form a stable complex on 18 bp DNA, but which forms two complexes on 37 bp 
DNA (Figure 2.4) as also seen for the mammalian two-HMG box protein HMGB1 [37]. 
 Ligase-mediated circularization of small DNA fragments has been extensively 
utilized as a means of comparing the DNA bending activities of non-sequence specific 
DNA bending proteins. Both HMGB1/2 and NHP6A/B catalyze formation of 66 bp 
circles, although NHP6A/B are more efficient [13, 41, 47]. This high efficiency has been 
attributed to the relative stability of NHP6A/B-DNA complexes compared to HMGB1/2 
and HU complexes [13, 41], but could also be due to a difference in the bend angle 
exerted by these proteins, with the angle exerted by NHP6A/B facilitating DNA strand 
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recognition by ligase [13]. HMO1 facilitated formation of circles only with DNA longer 
than 87 bp DNA (Figure 2.9), a lower efficiency that may correspond to either a reduced 
bend angle or a short residence time of HMO1 on linear DNA. 
 Work by Lu et al. [30] reports that HMO1 introduces negative supercoils into 
relaxed plasmid DNA, and that at high concentrations, HMO1 inhibits the unwinding 
reaction. We did not find evidence that HMO1 has the capability to introduce supercoils 
into relaxed plasmid DNA (Figure 2.10). In our work, we used recombinant HMO1, 
while Lu et al. purified HMO1 from yeast on the basis of its association with a DNA 
helicase activity, potentially resulting in isolation of posttranslationally modified protein 
[30]. SRY, which is a modestly sequence specific HMGB protein, also failed to supercoil 
relaxed DNA in the presence of topoisomerase I [45]. At position 37 of helix II where 
intercalating hydrophobic residues are located for non-sequence specific HMGB proteins, 
SRY has asparagine (Figure 2.1). Since the HMO1 box B and SRY both lack a 
hydrophobic residue at position 37, this may correlate with their intrinsic inability to 
supercoil relaxed DNA.  
 DNA minicircles most likely resemble possible distorted DNA targets, including 
features of chromatin structure, DNA topology during recombination, or bends 
introduced during transcription initiation. For HMO1, a much higher mass excess of 
plasmid DNA was required to compete for binding compared to complexes involving 
linear DNA (Figure 2.8). Presumably, the complex formed with the minicircle is less 
dynamic compared to complexes involving linear DNA. This increased residence time is 
probably a consequence of an optimized fit between the minicircle and HMO1. The more 
stable association of HMO1 with constrained DNA is consistent with its role in 
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maintaining the integrity of chromatin and in assembly of the rRNA preinitiation 
complex [30, 32]. 
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CHAPTER 3 
A ROLE FOR THE SACCHAROMYCES CEREVISIAE HIGH MOBILITY 
GROUP BOX PROTEIN HMO1 BEYOND DNA BINDING  
 
Introduction 
 High-Mobility-Group (HMG) proteins are a family of ubiquitous proteins that 
constitute a significant fraction of non-histone nuclear proteins and are grouped into three 
subfamilies, HMGA, HMGB, and HMGN [1-7]. These proteins are united by a common 
theme in that they bind DNA or nucleosomes, altering the local conformation, therefore 
increasing their accessibility and plasticity. Consequently, this facilitates and enhances 
various DNA-dependent activities such as transcription, replication, recombination and 
DNA repair (reviewed in [3, 6]). These three subfamilies have a unique protein signature 
and a characteristic functional motif, such as the HMG-box in HMGBs, the AT-hook in 
HMGAs, and the nucleosomal binding domain in HMGNs [2, 3, 6, 7].  
 HMGB proteins contain one or more homologous repeats of the ~80-amino acid 
sequence HMG box.  They bind to DNA in the minor groove and bend DNA ~90° 
towards the major groove. HMGB proteins are classified into two families based on the 
abundance, function and DNA specificity of the HMG box [1, 3, 6, 8]. The moderately 
sequence specific family are transcription factors that usually contain a single HMG box, 
for example transcription factors such as sex-determining factor SRY and lymphoid 
enhancer factor LEF-1 [9, 10]. The non-sequence specific family binds DNA without 
sequence preference but instead structural preference. They are represented by the so-
called architectural factors HMGB1/2, ubiquitous proteins in vertebrates, and the 
Saccharomyces cerevisiae non-histone chromosomal protein 6A and 6B (NHP6A/B) 
[11].  
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 A recent global analysis of protein expression in yeast showed HMGB proteins 
NHP6A/B and HMO1/2 to be present in the nucleus at moderately abundant levels [12]. 
NHP6A contains only one HMG box, which is 45% identical to rat HMGB1 box B and 
80% identical to NHP6B [13]. NHP6B is a functional paralog of NHP6A, and their 
biological function was determined using gene deletion experiments; a phenotype is only 
observed in the nhp6a/b double knockout. Double mutant (nhp6∆∆) cells exhibit 50% 
reduction in growth rate at 30°C and cannot grow at 37°C in the absence of osmotic 
support [14]. NHP6 has multiple roles in transcription, including transcriptional initiation 
and elongation by Pol II and transcription by Pol III [15, 16]. For example, it has been 
shown that the nhp6∆∆ growth defect can be suppressed by a multicopy plasmid with 
either SNR6 or BRF1 [15]; SNR6 encodes the U6 RNA required for mRNA splicing, and 
it is suggested that a deficiency in SNR6 RNA contributes to the temperature-sensitive 
growth defect seen in nhp6∆∆. BRF1 is the limiting component in TFIIIB, a factor 
required for Pol III transcription [17]. It is therefore likely that overexpression of BRF1 
increases SNR6 expression which in turn facilitates the growth of nhp6∆∆ at 37°C. 
Overexpression of TATA-binding protein (TBP) also suppresses the temperature-
sensitive growth defect of nhp6∆∆ [18]. TBP overexpression could suppress the nhp6∆∆ 
growth defect by affecting either Pol II or Pol III transcription because in addition to its 
well-documented role in Pol II transcription, TBP is also a component of the RNA Pol III 
initiation factor TFIIIB[16, 19]. It has also been demonstrated that NHP6 is required for 
maximal transcription of the HO endonuclease gene [20, 21]. For its role in elongation, 
NHP6 interacts genetically and biochemically with SPT16/POB3 [22, 23], the yeast 
equivalent of FACT (FAcilitates Chromatin Transcription, which is an accessory factor 
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present in HeLa cell nuclear extract) that promotes elongation through chromatin 
templates [24]. NHP6 is required for SPT16/POB3 to bind to nucleosomes [23, 25]. 
 HMO1 and HMO2 are ~25 kDa HMG-box proteins, identified by homology-
based motif-prediction programs as having only a single HMG-box, in a position 
corresponding to box B of mammalian HMGB. However, HMO1 also contains an N-
terminal box A domain with weak similarity to consensus HMG-box domains, which was 
recently shown to participate in DNA binding [26], and a long run of basic residues in the 
C-terminus, not found in any other HMGB proteins. Strains bearing HMO1 or HMO2 
mutant alleles are viable, although HMO1 mutant strains have growth defects, 
compromised plasmid maintenance and nuclease sensitive chromatin, suggesting that 
HMO1 may play a role in stability of the chromatin structure. A double knock-out of 
HMO1 HMO2 could not be rescued by addition of an osmotic stabilizer to the medium at 
37°C as with nhp6∆∆, indicating that the mutant was not defective in osmotic tolerance 
[27]. These authors also did not find any apparent synthetic phenotype of a triple mutant 
nhp6a, nhp6b, hmo1suggesting that there is no functional overlap of these proteins in the 
cells. In vivo, the HMO1 C-terminus is dispensible for function whereas HMG Box B is 
essential [27]. As the basic C-terminus is predicted to harbor the nuclear localization 
signal, an important implication of this observation is that the growth phenotype 
characteristic of the hmo1 knockout may be reversed by HMO1 mutant protein that is 
confined to the cytoplasm. Immuno-localization experiments have shown that full length 
HMO1 is present both in the nucleus and cytoplasm [27].  
 Here we report generation of various combinations of NHP6, HMO1 and HMO2 
mutant strains. It is evident from the data obtained that certain HMO2 mutant strains have 
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a slower growth phenotype, contrary to the previous report [27]. Using fusions to green 
fluorescent protein (GFP), we show that a HMO1 mutant deleted for the C-terminal tail 
(HMO1-boxAB) was localized to the cytoplasm. In contrast, HMO1-GFP was distributed 
both in the nucleus and the cytoplasm, as previously reported [27, 28]. As also reported 
by Lu et al. [27], we find that growth rates of yeast strains expressing HMO1-GFP and 
HMO1-boxAB-GFP were the same. This is indicative of essential and unique functions 
of HMO1 protein in the cytoplasm, and not in the nucleus.  
Experimental Procedures 
Strains, gene disruption and expression 
 All the original strains used are listed in Table 3.1A and some of the generated 
strains are listed in Table 3.1B. Standard genetic methods were used for strain 
construction and gene disruption. Prototroph selection markers TRP1 and URA3 were 
amplified from pRS424 and pRS426 plasmids, previously constructed and published by 
Christianson et al. [29]. The of primers used for HMO1 and HMO2 gene disruptions are 
listed in Table 3.2A. To amplify the selection marker with homologous sequence (~80 
nucleotides) upstream and downstream of HMO1 for gene disruption, HMO1F and 
HMO1R were used. For HMO2 gene disruption, HMO2F and HMO2R primers were 
used. Ten µg of PCR product was used to transform DDY3 haploid yeast cells selecting 
for tryptophan or uracil  prototrophy. Transformants were assayed by genomic PCR with 
one primer specific for chromosomal sequence upstream of the HMO1 or HMO2 open 
reading frames and the second primer (universal) specific for the integrated selection 
marker, to determine whether the selection marker had integrated at the appropriate locus 
(Figure 3.1). The primer used to amplify the upstream region of HMO1 was HMO1UF  
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Table 3.1 Yeast strains used in the experiments. A. Original strains. B. Yeast strains 
generated in this work.   
 
A                                                 
 
DDY3                  MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 GAL can1-100 
DDY587              MATα ade2 can1 his3 leu2 LYS2 trp1 ura3 nhp6a:URA3 nhp6b:HIS3 
DDY591             MATα ade2 can1 his3 leu2 LYS2 trp1 ura3 nhp6a:KanMX nhp6b:ADE2 
 
B                        
 
DDY1295            MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 hmo1∆::TRP1 
DDY1301            MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 hmo2::URA3 
DDY1329            MATα ADE2 his3 leu2 LYS2 trp1 ura3 hmo1∆::TRP1  
                             nhp6b:HIS3 
DDY1333           MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 hmo2::URA3   
                             nhp6a:KanMX 
DDY1385           MATa ade2 can1 his3 leu2 LYS2 trp1 ura3 hmo1∆::TRP1  
                             hmo2∆::URA3 nhp6a:KanMX nhp6b:HIS3 
DDY1386           MATa ADE2 his3 leu2 lys2∆ trp1 ura3 hmo1∆::TRP1  
                            hmo2∆::URA3 nhp6a:KanMX nhp6b:HIS3 
DDY1387           MATa ADE2 his3 leu2 LYS2 trp1 ura3 hmo1∆::TRP1  
                            hmo2∆::URA3 nhp6a:KanMX nhp6b:HIS3 
DDY1429           MATα ADE2 his3 leu2 lys2∆ trp1 ura3 hmo1∆::TRP1  
                            hmo2∆::URA3  
DDY1430          MATa ADE2 his3 leu2 lys2∆ trp1 ura3 hmo1∆::TRP1  
                            hmo2∆::URA3  
 
 
 
Strain                                                               Genotype 
Strain                                                               Genotype 
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Table 3.1 List of primers used. A. Primers used for to disrupt HMO1 and HMO2 genes 
in the original DDY3 strain. B. Primers used for generation of GFP-tagged HMO1 and 
HMO1-boxAB protein. Nucleotide sequence in upper case is the sequence homology to 
the desired chromosomal insertion site and the lower case is the sequence homology to 
the vector pFA6a-GFP.  
 
A                                    PCR primers used for gene disruption 
 
HMO1F      CCCAGCGGGCCCTCAGGGCTGGTCTACTGCCTTATACTCTAGGATGTACATCC 
                     TACCACACACAACAAGCCTGTCACACCGCAGATTGTACTGAGAGTGC  
 
HMO1R     TATATTTTATTCCTTTTTTTATTATTATATTTATTTTAGAAAGACAGTAGAGT 
                 AATAGTAACGAGTTTGTCCGTCCATCACTCCTTACGCATCTGTGCGG  
 
HMO2F     GCACATATATATTAAATCGTTCTAGGGGCTAGAATTGGATGAGAAGCAGCCAGG 
                    ATATAGGTAATAGTAACACATAAGAAGCAGATTGTACTGAGAGTGC 
 
HMO2R      TTGAACAATTTCTGGATAAAGCGCCTAGAACGTCTTACGATATCTTCAAAGAAA 
                     ATAGAAAAAAATGGAATTTTTAATTTCTCCTTACGCATCTGTGCGG 
 
HMO1UF    ACCCGACTCGATTATCTACC 
HMO2UF    GTGCTAAGAAATCTTGTGCACG 
UU               GCACTCTCAGTACAATCTGC    
HMO1DF    GGATTATGAGTTTCCTGAACAC   
HMO2DF    TGGTAATAAAAGCCACGTCTAG 
DD               CCGCACAGATGCGTAAGGAG 
 
B                           PCR primers used for generation of GFP-tagged protein 
 
HMO1-GFPF    GAAGAAGGATAAGAAGAAGGACAAATCCAACTCTTCTATTggtcgacggatccccggg 
 
HMO1-GFPR    AGAAAGACAGTAGAGTAATAFTAACGAGTTTGTCCGTCCAtcgatgaattcgagctcgtt 
 
boxAB-GFPF    CCAACTCATGCGCCGGTTCCAATTCCTTTCAGTTTACAGCACGCCggtcgacggatc 
                           cccgggtt 
 
 
 
Primer name                           Nucleotide sequence   (5′         3′)                        
Primer name                            Nucleotide sequence   (5′   3′)                        
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Figure 3.1 Strategy for generation of HMO1 or HMO2 knockout. DDY 3 cells were 
transformed with PCR products containing the selectable marker gene and sequence 
homologous to the upstream and down stream of gene of interest (black region on the PCR 
product), HMO1 or HMO2.  Through homologous recombination, HMO1 or HMO2 was 
knocked out and replaced with the integrated selectable marker. Transformants were 
assayed by genomic PCR with one primer specific for chromosomal sequence upstream of 
the HMO1 or HMO2 open reading frames and the second primer (universal) specific for the 
integrated selection marker, to determine whether the selection marker had integrated at the 
appropriate locus. The position and direction of the primers is shown as arrows.  
 
 
 
 
 
 
 
 
 
HMO1/2 
Selection marker 
Integrated marker 
PCR product 
Chromosomal 
HMO1 locus 
Selection marker 
Integrated in the 
chromosome 
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and HMO2 was HMO2UF. The upstream universal reverse primer was UU. The 
sequence of the primer used to amplify the downstream region for HMO1 was HMO1DF 
and HMO2 was HMO2DF and the downstream universal reverse primer sequence DD 
(Table 3.2A). The hmo1∆ (DDY1295) and hmo2∆ (DDY1301) mutant strains were 
generated. DDY1329 was generated by mating DDY587 with DDY1295 and selecting 
for prototrophy tryptophan (HMO1) and histidine 3 (NHP6B). DDY1333 was generated 
by mating DDY591 with DDY1301 and selecting for uracil prototrophy (HMO2) and 
antibiotic Kanamycin antibiotic resistance (NHP6A). DDY1333 and DDY1329 cells 
were mated and grown in sporulation media for tetrad dissection. 
Construction and analysis of GFP-tagged HMO1 and HMO1-boxAB 
 HMO1 was C-terminally tagged with GFP at its chromosomal location through 
oligonucleotide-directed homologous recombination (Figure 3.2). To generate HMO1-
GFP, a pair of oligonucleotides were generated that had homology to the C-terminus of 
HMO1 (upper case in the primer sequence), which was the desired chromosomal 
insertion site at the 5' end of each primer and homology to vector pFA6a-GFP (F64L, 
S65T, R80Q, V163A)-His3MX6 (lower case in the primer sequence) containing the GFP 
tag and Histidine 3 as the auxotrophic marker at the 3' end. Vector pFA6a-GFP was 
kindly provided by Dr. Mark Longtine [30]. To generate HMO1-GFP, the forward primer 
used was HMO1-GFPF and the reverse primer used was HMO1-GFPR. To generate 
HMO1-boxAB, the forward primer was designed such that the sequence homology of the 
oligonucleotides deleted 36 amino acids from the C-terminus. The forward primer used 
was boxAB-GFPF and the same reverse primer as for HMO1 was used. The PCR 
products were used to transform DDY3 cells. Cells were grown in YMD-His media  
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Figure 3.2 Strategy for generation of HMO1-GFP or HMO1-boxAB-GFP fusion 
protein. DDY cells were transformed with PCR products containing the GFP tag and 
HIS3 auxotrophic marker gene. The GFP was inserted at the C terminus of HMO1 or 
HMO1-boxAB through homologous recombination, yielding a C-terminally GFP-tagged 
protein. 
 
 
 
 
 
 
 
 
 
 
 
PCR product 
Chromosome 
    HMO1/2 
Fusion protein 
Homologous 
recombination 
GFP HIS3MX6 
HMO1/2 ORF 
HMO1/2 Protein GFP HIS3MX6 protein 
 66
(minimal media lacking histidine), to select for cells that had integrated the auxotrophic 
selection marker gene into their chromosome.  Transformants were assayed by genomic 
PCR with one primer specific for the GFP tag and a second specific for the 
HMO1/HMO1-boxAB open reading frame, to determine whether the cassette had 
integrated at the appropriate locus. The PCR product obtained was sequenced to ensure 
that the gene cassette had been integrated at the appropriate locus in-frame. The cells 
were then analyzed by multiple wavelength fluorescence and visible light microscopy 
with digital imaging-capable using at x40 magnification.   
Results 
Characterization of mutant phenotypes 
 DDY1333 (hmo2, nhp6a)  was mated with DDY1329 (hmo1, nhp6b), sporulated 
and subjected to tetrad analysis (Figure 3.3). Four viable spores were obtained showing 
that none of the four genes are essential for viability as previously shown [27]. Colonies 
were visually analyzed, looking at the sizes and light intensity. Table 3.3 shows the genes 
that were inactivated from each spore in Figure 3.3. Although the quadruple knockout 
was viable, it gave rise to the smallest colonies (A2, data not shown).  Triple knockouts 
C1 (hmo1, hmo2, nhp6a) and A5 (hmo1, nhp6a, nhp6b) gave the second smallest 
colonies after the quadruple knockout. The ∆nhp6a, ∆nhp6b and ∆hmo2 single knockouts 
did not show any phenotype (compare B2, C2, D3, A4, B5, C5 to the wildtype A1). 
Interestingly, when the HMO2 gene was deleted in the context of an HMO1 knockout, 
slightly smaller colonies with lower light intensity compared to ∆hmo1 (D2, C3) were 
obtained (A3, D4, A6). It is also noteworthy to compare colony C1 to B4; the slightly  
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Figure 3.3 Phenotype of various mutants from a tetrad dissection. DDY1333 was 
mated with DDY1329, sporulated and subjected to tetrad analysis. Spores were 
germinated and grown on YPD plate for 3 days at 30°C. The genotype of each spore was 
scored using the standard method, by replica plating to minimal media lacking the 
nutrient corresponding to each marker gene (or containing G418 for the KanMX marker) 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
B 
C 
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 68
TABLE 3.3 Tetrad analysis 
                                                 
 
    A1                                                                   None 
    B1                                                       NHP6A, NHP6B, HMO2 
    C1                                                       NHP6A, HMO1, HMO2 
    D1                                                       HMO1, HMO2 
 
    A2                                                       NHP6A, NHP6B, HMO1, HMO2 
    B2                                                       NHP6A 
    C2                                                       NHP6B, HMO2 
    D2                                                       HMO1 
 
    A3                                                       HMO1, HMO2 
    B3                                                       NHP6A, NHP6B, HMO2 
    C3                                                       HMO1 
    D3                                                       NHP6A, HMO2 
 
    A4                                                       NHP6B, HMO2 
    B4                                                       NHP6A, HMO1 
    C4                                                       NHP6A, NHP6B 
    D4                                                       HMO1, HMO2 
 
    A5                                                       NHP6A, NHP6B, HMO1 
    B5                                                       HMO2 
    C5                                                       NHP6A 
    D5                                                       NHP6B, HMO1, HMO2 
 
    A6                                                       HMO1, HMO2 
    B6                                                       NHP6A 
    C6                                                       HMO1, HMO2, NHP6B 
    D6                                                       NHP6A, NHP6B 
 
 
 
 
 
 
 
 
 
Spore location in Figure 3.2                     Genes Knocked out 
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larger B4 colony is ∆nhp6a ∆hmo1, while C1 is ∆nhp6a ∆hmo1 ∆hmo2, indicating that 
the difference in size is due to a ∆hmo2 phenotype. ∆hmo1 ∆hmo2 (A3, D4, A6) have 
smaller colonies with less light intensity compared to ∆∆nhp6 (C4, D6) whereas ∆hmo1 
(D2, C3) compares to ∆∆nhp6. While the previously reported absence of a growth 
phenotype upon inactivation of hmo2 was inferred based on comparison to wild type 
cells, our data show that a growth phenotype may be detected in an hmo1 mutant 
background. 
Localization of HMO1-GFP and HMO1-boxAB-GFP in yeast cells 
 HMO1 has previously been shown to be both a nuclear and cytoplasmic protein 
[27, 31]. In these experiments, we confirm the localization of HMO1-GFP to both the 
nucleus and the cytoplasm. However, HMO1-boxAB-GFP was localized only in the 
cytoplasm (Figure 3.4). Lu et al. [27] showed that a plasmid expressing the full length 
HMO1 or HMO1-boxAB complemented the hmo1 mutant phenotype, but a plasmid 
expressing HMO1 deleted for 30 amino acids of box B did not. This implies that the 
ability of HMO1 to rescue the hmo1 mutant phenotype is in the cytoplasm and not in the 
nucleus.  This also confirms that the Nuclear Localization Signal (NLS) of HMO1 is 
located at the C-terminus as predicted by the NLS prediction program on the 
www.expasy.org website.  
Discussion 
Growth phenotype 
 HMO1 was first identified by its co-purification with a DNA helicase. 
Genetically, HMO1 was shown to be required for normal growth, plasmid maintenance 
and for regulating susceptibility of yeast chromatin to nuclease [27]. These authors  
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Figure 3.4 In vivo localization of HMO1-GFP and HMO1-boxAB-GFP proteins. A. 
HMO1-GFP is distributed both in the nucleus and the cytoplasm. The image on the right 
panel is the face contrast shot of the same cell. B. HMO1-boxAB-GFP is distributed in 
the cytoplasm. The image on the right panel is the face contrast shot of the same cell. 
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proposed that HMO1 binds to the small linker DNA of yeast, stabilizing a higher-order 
chromatin structure which is important for normal gene expression and/or DNA 
replication. Dolinski and Heitmain [31] showed that HMO1 interacts genetically and 
physically with FKBP12 Prolyl Isomerase. HMO1 has also recently been identified as a 
genuine RNA polymerase I, factor acting synergistically with Rpa49 (DNA-directed 
RNA polymerase I 49 kDa polypeptide, which is a non-essential but conserved subunit of 
RNA polymerase I corresponding to the animal RNA polymerase factor PAF53) during 
rDNA transcription [32].  In this study, we have shown that the unique functions of 
HMO1 are  confined to the cytoplasm.  Lu et al. [27] noted that HMO1 mutants were 
viable most likely because other proteins performed the essential functions of HMO1, 
although they might lack the abundance or binding properties to optimally replace loss of 
HMO1. In fact, a recent global analysis of protein expression in yeast revealed HMO1 as 
the most abundant HMGB protein in yeast [33]. By virtue of it abundance, HMO1 can 
likely protect the chromatin from nuclease digestion as observed for hmo1∆ [27]. These 
authors also showed that NHP6 had non-overlapping functions with HMO1 in the cell. 
Therefore, it is most likely that HMO2 would replace the function of HMO1 in the cell. 
In comparison to other HMGB proteins, both HMO proteins have a divergent A box  
where conserved and charged residues have been replaced by unrelated residues. The B 
box however, is highly conserved showing higher identity with the consensus. HMO2 
lacks the unique highly basic C-terminal tail found in HMO1. Interestingly, we have 
observed a slight slow growth HMO2 phenotype that is only evident in hmo1 hmo2 
mutant strains (Figure 3.2 , Table 3.2). ∆hmo2 alone does not show any apparent 
phenotype, most likely because the more abundantly expressed HMO1 takes over the 
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function of HMO2. In addition, the lack of a synthetic phenotype between NHP6 and 
HMO2 suggests that they have non-overlapping functions in the cell as well (Figure 3.2, 
compare spores B3 to D6), further confirming that HMO1 is the likely protein that 
replaces the function of HMO2 in ∆hmo2 cells, and HMO2 replaces some of the 
functions of HMO1 in ∆hmo1 cells. Overexpression of HMO2 in ∆hmo1 strains would 
address this hypothesis.  
Cellular localization 
 The C-terminus of HMO1 is dispensible for function in vivo [27]. These authors 
showed that a plasmid expressing the full length HMO1 or HMO1-boxAB complemented 
the mutant phenotype. Interestingly, we have localized HMO1-boxAB to the cytoplasm 
(Figure 3.4). This is a clear indication that the essential and unique functions of HMO1 
are located in the cytoplasm and not in the nucleus. This data is supported by the fact that 
HMO1 genetically and physically interacts with cytoplasmically expressed FKBP12 
Prolyl Isomerase,  a product of the FPR1 gene, which when mutated has been shown to 
be synthetic lethal with ∆hmo1[31]. We have previously shown that HMO1 has distinct 
DNA binding and bending properties from other HMGB proteins, consistent with its 
unique role in vivo [26]. Although HMO1 was speculated to play a role in organizing 
target structures for yeast RNA polymerase I-dependent transcription, direct interaction 
between HMO1 and Rpa49 or RNA polymerase I was not detected [32]. S. cerevisiae  
SPT16/CDC68 and POB3 (Polymerase one-binding) form a heterodimer, localizes to the 
nucleus and have been shown to affect DNA replication and transcription globally [23, 
33, 34, 35]. STP16 and POB3 show strong genetic interactions with NHP6 but only 
minor interactions with HMO1 or HMO2 [23, 27]. 
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 Lu et al.[27] described HMO1 as a likely homolog of HMGB1/2. HMGB1 has 
been considered as a ubiquitous nuclear protein with an architectural function, but it had 
also been described to be present in the cytoplasm [36]. Today, extranuclear and 
extracellular functions of HMGB1 have just started to come into focus. It participates in 
developmental and differentiation processes, triggers and modulates many of the 
inflammatory cascades in the body, and may even be involved in the metastatic invasion 
programme of cancer cells (reviewed in [37]). Similarly, our data indicate that HMO1 has 
extracellular functions which may or may not be similar to those of HMGB1. Notably, 
signaling by TOR (Target of Rapamycin) kinases is central to environmental stress 
responses in yeast. Suppression of TOR signaling, for example through inhibition of TOR 
kinases by interaction with FKBP12-rapamycin, leads to cell cycle arrest (reviewed in 
[38]). The reported interaction between HMO1 and FKBP12 suggest a possible role for 
HMO1 in such signaling pathways. Studies to characterize the extranuclear function of 
HMO1 will further expand signaling roles of HMGB proteins beyond HMGB1, which 
thus far is the only HMGB protein that has been shown to have signaling capabilities, 
expanding the importance of HMGB proteins across organisms.  
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 CHAPTER 4 
 
PHOSPHORYLATION OF SACCHAROMYCES CEREVISIAE HIGH MOBILITY 
GROUP BOX PROTEIN HMO1 BY CASEIN KINASE II AND THE ROLE OF 
THE C-TERMINAL DOMAIN IN DNA BINDING AND PROTEIN STABILITY  
  
Introduction 
 
 High-Mobility-Group (HMG) proteins are relatively abundant non-histone 
nuclear proteins with one or more homologous DNA binding domains, the HMG box, 
each of ~80-amino acid residues. HMGB proteins are classified into two families based 
on their abundance, function and DNA specificity [1-5]. Some are transcription factors 
that bind DNA with sequence-specificity; they usually contain a single HMG box and are 
expressed in a few cell types [6]. They are exemplified by sex-determining factor SRY 
and lymphoid enhancer factor LEF-1 [7, 8]. The non-sequence-specific family binds 
DNA without sequence preference but instead structural preference. They are typified by 
HMGB1/2, ubiquitous, vertebrate, non-sequence specific HMGB proteins, and 
Saccharomyces cerevisiae non-histone chromosomal proteins 6A and 6B (NHP6A/B) [3, 
9, 10]. The role of HMGB1 in regulation of transcription, either by remodeling chromatin 
and nucleosome structure or through direct interaction with transcription factors such as 
Hox, steroid hormone receptors, p53, NF- B, and TBP is well documented (reviewed in 
[11]). The HMGB1 knockout mouse dies shortly after birth due to hypoglycemia from a 
defect in the transcriptional function of the glucocorticoid receptor [12]. Outside the cell, 
HMGB1 functions as a cytokine [13, 14] and is a ligand for a membrane receptor, RAGE 
[15, 16]. 
 The structures of HMG boxes both from the non-sequence and the sequence 
specific subfamilies have been determined in the presence and/or absence of DNA, 
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revealing a general global fold, characterized by a 3-dimensional, L-shaped structure with 
three α-helices (reviewed in [11, 12]). The HMG box binds to the DNA minor grove by 
partial intercalation of one or two conserved hydrophobic residues, causing the DNA to 
be highly distorted, resulting in a sharp bend and helical underwinding [8, 17, 18, 19, 20].  
 Posttranslational modification of HMGB proteins has been reported, but the 
functional significance of these modifications, except for the acetylation, is unknown 
[21]. Phosphorylation of HMG proteins appears to be a common posttranslational 
modification that is found in evolutionarily distant organisms [22]. For example, pulse-
labeling studies on phosphorylation of the Chironomus HMGB1a and HMGB1b proteins 
showed that these proteins are phosphorylated by protein kinase C [23] and by Casein 
kinase II (CKII) [22]. Broccoli (Brassica oleracea) HMGB protein was found to co-
purify with CKII with very high affinity and was efficiently phosphorylated even in the 
presence of an excess of exogenous substrates [24]. CKIIα phosphorylates the acidic C-
terminal domain of the HMGB1 and HMGB2/3 proteins [25]. HMG phosphorylation 
appears to alter the conformation, stability, and DNA binding properties of these proteins 
and is therefore essential for their function. For example, DNA supercoiling properties of 
HMGB1 were shown to be modified by phosphorylation [25, 26].  
 Basic extensions found either C- or N-terminal to the HMG box are known to 
increase the bending capacity and DNA-binding affinity of the HMG box. For example, 
the 16 basic amino acids found at the N-terminus of the NHP6A HMG box is required for 
stable complex formation on both linear DNA and DNA minicircles [20]. Basic C-
terminal extensions stabilize binding of HMG-D and LEF-1 by binding in the major 
groove opposite the distorted minor grove [8, 27].  
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 The HMGB1/2 acidic tail has been shown to lower the affinity of the HMG boxes 
for most DNA substrates, such as linear DNA, supercoiled DNA and 4-way junction 
(reviewed in [28]). Interestingly, the tail is not important for structure-selective DNA-
binding of the HMG boxes to DNA minicircles since it has little effect on the affinity for 
DNA minicircles compared to other DNA substrates in vitro [29]. However, it was not 
established whether this is a consequence of interaction of the tail with the HMG box(es) 
or the basic extension region or simply charge repulsion. Thomsen et al. [30] showed that 
interactions of the basic N-terminal and acidic C-terminal domains of the maize HMGB1 
may contribute to regulation of the DNA interactions of the protein. A similar 
phenomenon was also observed for Arabidopsis HMGB1 and HMGB4 [30]. This led the 
authors to argue that the interaction of the variable terminal domains of the different plant 
HMGB proteins could serve as a molecular mechanism involved in the fine tuning of the 
functional properties of these architectural proteins, depending on the structural 
requirements of specific nucleoprotein complexes.  
   S. cerevisiae contains several HMG-box proteins. For example, HMO1 is 
identified by homology-based motif-prediction programs as having only a single HMG-
box, in a position corresponding to box B of mammalian HMGB1. However, HMO1 also 
contains an N-terminal box A domain with weak similarity to consensus HMG-box 
domains. HMO1 and HMO2 genes are non-essential, but deletion of HMO1 gene confers 
growth defects, impaired plasmid maintenance and nuclease sensitive chromatin [31]. 
HMO1 has also been shown to interact with FKBP12, an abundant protein that interacts 
with a number of cellular proteins, including the target of Rapamycin (TOR) kinases that, 
for example, regulate rDNA transcription [32, 33]. A recent study includes HMO1 
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directly in the rRNA transcription apparatus, where it was proposed to function in a 
similar capacity as the Upstream Binding Factor (UBF), an auxiliary factor in the 
mammalian and amphibian RNA Polymerase I transcription systems; UBF has six HMG 
domains [34].  
 We have previously shown that the divergent HMO1 box A domain participates 
in DNA binding, and that it contributes modest structure-specific DNA binding to 
HMO1, while box B confers most of the DNA binding affinity [35]. In this study we 
show that HMO1 and HMO1 deleted of its C-terminal tail (HMO1-boxAB) get 
phosphorylated by CKII, yielding proteins with reduced affinity for DNA. These data 
suggest that HMO1 can be regulated by posttranslational modification. We have also 
analyzed the role of the HMO1 basic C-terminal tail in DNA binding. Circular Dichroism 
(CD) Spectroscopy measurements of protein melting temperatures revealed that HMO1-
boxAB has a higher melting temperature than the wild type, suggesting that the C-
terminal domain destabilizes the protein. 
Experimental Procedures 
Cloning and Purification of Proteins 
 The gene encoding HMO1 was amplified from yeast genomic DNA and 
subcloned into pET28b for expression with an N-terminal His6-tag. HMO1-boxA was 
generated as previously described [35]. To generate HMO1-boxAB, PCR-based site-
directed mutagenesis was used to replace Ala210 with a stop codon. The sequence of the 
primers used are available upon request. Recombinant plasmids were used to transform 
E. coli Rosetta Blue strain (Novagen). Proteins were purified as previously described 
[35].  
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Circular Dichroism Spectroscopy 
 CD spectra were recorded on an AVIV Model 202 CD spectrophotometer using a 
1 cm pathlength sample cell. Wavelength scans from 200 nm to 300 nm were performed 
in triplicate, and data points were averaged and smoothed using standard methods. The 
wavelength scan for His6-tagged HMO1 was recorded at 25ºC, with a protein 
concentration of 0.025 mg/ml in 2.5 mM NaxHyPO4, pH 7.0, 0.5% glycerol, 10 mM 
NaCl. The wavelength scan for His6-tagged HMO1-BoxA was recorded at 4ºC, using a 
protein concentration of 0.05 mg/ml in 1 mM Tris, pH 7.0, 0.03% Tween 20, 10% 
glycerol, 2.8 mM KCl.  For measurement of thermal stability, protein was diluted to 0.05 
mg/ml in CD buffer (20 mM potassium phosphate (pH 7), 8 µM EDTA, 0.2% glycerol, 3 
mM KCl), and measurements were made using a quartz cuvette with a 1-cm path length. 
Ellipticity readings from 300 to 200 nm (1-nm steps) were taken over the temperature 
range 19–70 °C, with steps of 3 °C (19–37 and 61–70 °C) or 1.5 °C (37–61 °C). Each 
sample also underwent a reverse scan from 67 to 19 °C. Three minutes were allowed for 
thermal equilibration after each step. Wavelength scans from 300 to 200 nm were 
performed at 19 and 70 °C to verify the native and denatured states of the protein, 
respectively. CD measurements of protein melting were performed in triplicate and 
corrected for buffer contributions to the signal. Calculation of the Tm of the proteins was 
made based on ellipticity measurements from 230 to 220 nm. Temperature-dependent 
ellipticity values were plotted at each wavelength and fit to a two-state model for protein 
unfolding [36]. The Tm is reported as the average ± S.D.  
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Electrophoretic Mobility Shift Assays (EMSA) with 26 bp duplex DNA and 4-way 
junction DNA 
 
 Four-way junctions were constructed as previously described; the sequence of 
individual strands are as described [35, 37]. Briefly, the 4-way junction was prepared by 
annealing the four strands, followed by purification of the junction on native 
polyacrylamide gels. To ensure that all oligonucleotides were present, aliquots of the 
purified junction were run on denaturing gels. EMSA was performed by incubating 
reactions at room temperature in 10 µl reaction buffer containing 5 fmol DNA and 
varying amounts of protein. Samples were resolved on prerun 7% (w/v) native 
polyacrylamide gels (39:1 acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE (50 mM 
Tris-borate, 1 mM EDTA) running buffer. Complexes were visualized by 
phosphorimaging. Experiments were done at least in duplicate, and values are reported as 
the mean ± standard deviation. For calculating fractional complex formation, the region 
on the gel from the slowest migrating complex to the free DNA was considered as 
complex and the binding isotherms for protein binding were fitted as described [35]. 
Ligase-Mediated Circularization 
  Ligation substrates were prepared by digestion of pET5a with BspHI to generate 
a 105 bp fragment. DNA was 5'-end labeled with T4 polynucleotide kinase and ( -31P) 
ATP. Reactions were initiated by addition of 20 units of T4 DNA ligase to a final volume 
of 100 µl reaction buffer (20 mM Tris-HCl pH 8, 50 mM NaCl, 10 mM MgCl2, 0.1 mM 
Na2EDTA, 1 mM DTT, 0.05% BRIJ58) containing 1200 fmol DNA, with or without the 
protein. Time points were taken at intervals over 30 minutes. For each time point, 8 µl of 
the reaction mixture was quenched by addition of 5 µl stop buffer (75 mM EDTA, 15% 
glycerol, 0.1% bromophenol blue (BPB), 0.1% xylene cyanol, 6 µg/µl proteinase K). 
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Samples were heated at 55°C for 15 minutes and resolved on prerun 7% (w/v) native 
polyacrylamide gels (39:1 acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE. 
Quantitation was performed on a Molecular Dynamics Storm Phosphorimager using 
software supplied by the manufacturer.  
Protein phosphorylation 
 Proteins were phosphorylated using Casein Kinase II (CKII, New England 
Biolabs) as per the manufactures recommendation. One µg of protein was incubated with 
1 unit of Casein Kinase II (CKII) in 1X CKII buffer (20 mM Tris-HCl pH 7.5, 50 mM 
KCl, 10 mM MgCl2) supplemented with 32P-ATP with a final specific activity of 200 
µCi/µmol in 10 µl final volume, and incubated at 30°C for one hour. Samples were run 
on a 15% SDS-PAGE and quantification was performed on Molecular Dynamics Storm 
Phosphorimager.   
Protein cross-linking  
 Protein was incubated with 0.1% glutaraldehyde in 10 mM sodium phosphate (pH 
7.0) at room temperature for 5 minutes. Samples were diluted 1:2 with SDS-sample 
buffer, and analyzed by electrophoresis on 17% SDS-PAGE followed by Coomassie blue 
staining. 
Proteolytic digestion with Enterokinase and BNPS-skatole 
 For Enterokinase digestion, 2 µg protein was incubated at room temperature with 
0.4 U Enterokinase (Novagen) in cleavage capture buffer (20 mM Tris pH 7.5, 50 mM 
NaCl, 2 mM CaCl2), and aliquots taken after various times. The cross-linking reaction 
was quenched by addition of 10 µl SDS-sample buffer and analyzed on 17% SDS-PAGE 
gels. Proteins were detected by staining with Coomassie brilliant blue. For BPNS-skatole 
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(2-(2-nitrophenyksulfenyl)-3-methyl-3-bromoindoleline) (Sigma) digestion, 2 µg of 
protein were incubated with 40 µl BPNS-skatole solution (1 mg/ml in 80% acetic acid 
and 01% phenol) in 35 µl acetic acid. After 36 h at room temperature, the samples were 
lyophilized and analyzed as described above. 
DNA Supercoiling  
 Reactions contained 0.2 µg relaxed closed circular pUC18 plasmid, prepared by 
adding 2.5 units of Vaccinia topoisomerase I (Epicentre) to supercoiled pUC18 in 
relaxation buffer (50 mM Tris, pH 7.5, 2.5 mM MgCl2, 100 mM NaCl and 0.1 mM 
EDTA). After 1.5 h at 37°C, varying amounts of protein were added and the reactions 
incubated for 1 h at 37°C. Reactions were quenched with 5 µl termination buffer (5X 
TBE, 5% SDS, 15% sucrose, 0.1% BPB, 0.1% xylene cyanol, 2 µg/µl proteinase K) and 
incubated for 1 h at 37°C. Samples were loaded on 1% 1X TBE agarose gels and 
electrophoresed at 2 V/cm for 12 h in 1X TBE buffer.  
Results 
CD spectra and Melting temperature 
 Recombinant N-terminally His6-tagged HMO1, HMO1-boxAB and HMO1-boxA 
were purified to apparent homogeneity, as judged by Coomassie Blue-staining of SDS-
PAGE gels (Figure 4.1, panel D). Based on CD spectra, we have previously shown that 
HMO1 and HMO1-boxA have high α-helical content [35]. However, the CD spectrum of 
HMO1-boxAB displayed only a single negative peak ellipticity at 222 nm (data not 
shown). In fact, this peak was only achieved in the presence of high detergent (0.1%  
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Figure 4.1 Thermal denaturation of HMO1 (A), HMO1-boxAB (B), HMO1-boxA (C). 
Ellipticity measurements were recorded from 4 °C to 90 °C at wavelengths from 221-230 
nm. D, SDS-PAGE showing purified His6-HMO1-boxA, His6-HMO1-boxAB and His6-
HMO1 in that order.  
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Tween 20 compared to 0.03% for HMO1-boxA) and low protein concentrations (0.02 
mg/ml compared to 0.05 mg/ml for HMO1-boxA, suggesting protein aggregation). 
Thermal denaturations of HMO1 and HMO1-boxAB were biphasic, a process consistent 
with a protein containing two distinct domains (Figure 4.1). HMO1 and HMO1-boxAB 
had melting temperatures of 23.5 ± 0.4°C and 57.6 ± 0.8°C, and 48.2 ± 2.0°C and 71.7 ± 
0.7°C respectively.  However, HMO1-boxA melting occurred in a single transition at 
52.2 ± 0.2°C, indicative of unfolding of a single domain (Figure 4.1). HMO1-boxAB had 
a higher melting temperature than HMO1; in addition, HMO1-boxA had a relatively high 
melting temperature compared to HMO1. This is an indication that the C-terminal tail 
destabilizes the protein. However, it is also possible that with deletion of the C-terminal 
tail, one domain became more stable (melting temperature increased from 23.5°C to 
71.7°C) while the other domain became less stable (melting temperature decreased from 
57.6°C to 48.2°C). Arguments to support the likelihood that the first transition is melting 
of box A and the second transition is melting of box B is presented in the discussion.  
HMO1-boxAB has lower affinity for DNA compared to the wild type protein  
 DNA binding was analyzed with Electrophoretic Mobility Shift Assays (EMSA). 
We have previously shown that HMO1 has only modest preference for DNA with altered 
conformations including the 4-way junction, which it binds with a half-maximal of 4.9 ± 
1.5 nM (see figure 4 in [35]). HMO1-boxAB bound 4-way junction with a half-maximal 
saturation of 27.9 ± 1.4 nM (Figure 4.2). The half-maximal values implicate participation 
of C-terminal tail in DNA binding, directly or indirectly. Basic extension regions of 
HMGB proteins have been shown to contribute to DNA binding properties [28, 30, 39].  
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Figure 4.2 Binding of HMO1 (panel A) and HMO1boxAB (panel B) to 4-way junction 
DNA. Reactions contain 5 fmol DNA, and protein concentrations are 0, 5, 7.5, 10, 25, 30, 
35, 40, 50, 100 and 120 nM. B, binding isotherms for HMO1 (solid line) and HMO1-
boxAB (broken line) on the 4-way junction DNA. Reactions were done in duplicate; 
values are reported as the mean ± S.D.   
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HMO1-boxAB does not bend DNA 
 Ligase-mediated circularization assays were performed where the efficiency with 
which T4 DNA ligase mediates ring closure of DNA fragments that are shorter than the 
persistence length is measured [20, 40]. The ability of HMO1-boxAB to enhance ligase-
mediated DNA circularization was qualitatively assessed with 105 duplex DNA. HMO1-
boxAB did not facilitate formation of minicircles, unlike HMO1 (Figure 4.3, [35]). It has 
been shown that deletion of the basic N-terminus of NHP6A yields a protein with low 
affinity for linear DNA that retains the ability to convert 40% of a 98 bp DNA fragment 
into minicircles, compared to 70% for the wild type [20].  In contrast, HMO1-boxAB 
bound linear duplex DNA with an affinity close to that of the wild type protein (data not 
shown), but could not bend the DNA. This shows that HMO1 and NHP6A bind and bend 
DNA differently. Conversely, incubation of DNA with C-terminal truncated HMGB1/2 
yielded DNA minicircles at lower concentrations, probably reflecting the high affinity for 
linear duplex DNA of these mutant proteins [28].  
HMO1 and HMO1-boxAB are substrates for CKII 
 Using programs available for prediction of protein phosphorylation sites 
(www.expasy.com), HMO1 was predicted to have many Ser/Thr residues that can be 
phosphorylated by different kinases. CKII is a structurally and functionally conserved 
enzyme that is widely distributed among eukaryotic organisms and previously shown to 
phosphorylate HMGB1. S. cerevisiae has four essential genes that make up the protein 
kinase CKII complex, CKA1, CHA2, CKB1 and CKB2. We therefore chose to use CKII 
for analysis of HMO1. CKII is predicted to target six potential HMO1 phosphorylation  
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Figure 4.3 Time-course ligation assay with 105 bp DNA. 100 fmol 105 bp linear DNA 
was incubated with 1250 nM protein (HMO1 top panel and HMO1-boxAB lower panel) 
up to 30 minutes. Time points were taken at 0, 0.5, 1, 2.5, 5, 10, 20, and 30 min. 
Exonuclease III was added to reactions in the last lane at 30 min time-points. Circular 
ligation products (the last lane top panel) were resistant to digestion by Exonuclease III. 
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sites at positions, Ser11, Ser19, Ser33, Try54, Ser137 and Ser153. Equal amounts of 
HMO1, HMO1-boxA and HMO1-boxAB were reacted with CKII and 32P-ATP. The 
phosphorylated proteins were resolved on SDS-PAGE gel, and 32P incorporation was 
determined using phosphorimaging (Figure 4.4).  HMO1 and HMO1-boxAB were 
phosphorylated, but HMO1-boxA was not. This data suggests that Ser137 and/or Ser153 
are the phosphorylation sites for HMO1 by CKII, as these sites are located in the box B 
domain. CKII is a 130 kDA protein with α2β2 tetrameric structure. The 44 kDA α subunit 
is catalytic and the 26 kDA β subunit is thought to have regulatory properties, but it also 
gets autophosphorylated. HMO1-boxAB migrates at the same rate as the β subunit; hence 
it was not possible to resolve its phosphorylation on this gel. EMSA was carried out to 
compare binding to 4-way junction DNA by HMO1 and HMO1-boxAB before and after 
phosphorylation. Phosphorylated proteins showed lower DNA binding affinity (Figure 
4.4). To investigate if phosphorylation of HMO1 changed its DNA bending properties, 
ligase-mediated circularization assays were performed with phosphorylated HMO1 (data 
not shown). There was no discernable difference in minicircle formation between 
phosphorylated and non-phosphorylated HMO1.   
HMO1 forms oligomeric complex in solution 
 Based on the molecular mass of HMO1 eluting from a sizing column, Lu et al. 
had predicted that HMO1 exists as an oligomeric complex in solution [31]. Cross-linking 
reagents can provide the means for capturing protein:protein complexes by covalently 
bonding them together as they interact. When HMO1 and HMO1-boxAB were incubated 
with 0.1% glutaraldehyde, they formed oligomeric complexes, as judged by SDS-PAGE 
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gel. However, HMO1-boxA formed oligomeric complexes, with dimers clearly forming 
(Figure 4.5).  
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Figure 4.4 (A) Phosphorylation of HMO1. Using 31P-ATP, HMO1 was phosphorylated 
with CKII, resolved on SDS-PAGE and scanned on a PhosphorImager. Lane 1 shows 
autophosphorylation of CKII. Lane 2 shows HMO1 phosphorylated. (B) DNA binding 
by phosphorylated HMO1 and HMO1-boxAB. HMO1 and HMO1-boxAb were 
phosphorylated and then used for EMSA with 4-way junction DNA. Lane 1 was the 
control with no protein. Increasing concentration (10, 20 or 40 nM) of phosphorylated or 
protein that has not been phosphorylated was used.   
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Figure 4.5 SDS-PAGE showing HMO1-boxA cross-linking.   Protein was incubated 
with 0.1% glutaraldehyde and time points taken at 2.5, 5 and 7.5 minutes, Lanes 2-4. 
Lane 1 has no glutaraldehyde. Reactions were stopped by adding 10µl SDS-PAGE 
sample buffer and loaded on a 17% gel.  
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Protein cleavage analysis 
 Many proteins undergo significant conformational changes after binding to a 
ligand. Such changes can be assessed by cleaving the protein at different locations using 
peptide cleavage reagents. Using programs available for prediction of peptide cleavage 
sites (www.expasy.com), HMO1 was predicted to have 2 Enterokinase cleavage sites 
(Lys48, Lys84) and 2 BNPS-skatole [2-(2-nitrophenylsulfenyl)-3-methylindole] cleavage 
sites (Trp149, Trp160). Enterokinase is a serine protease that recognizes the amino acid  
sequence -Asp-Asp-Asp-Lys-|-X and activates its natural substrate trypsinogen and 
releases trypsin by cleavage at the C-terminal end of this sequence. BNPS-skatole is a 
mild oxidant and brominating reagent that leads to polypeptide cleavage on the C-
terminal side of tryptophan residues. It was evident from appearance of fast migrating 
protein fragments on SDS-PAGE gel, which corresponded to the cleaved protein 
fragments of appropriate sizes, that HMO1 and HMO1-boxAB were cleaved by both 
reagents as expected (Figure 4.6). However, addition of DNA to the reactions did not 
change the cleavage pattern. This shows that the binding of HMO1 and HMO1-boxAB to 
DNA substrate does not cause significant conformation change to alter the accessibility 
of the amino acids cleaved by these reagents.  
Discussion 
Interdomain interactions in HMO1 
 Based on thermal melting of HMGB1, Ramstein et al. [41] proposed that HMGB1 
box A and B behave as independent domains in a protein truncated of the acidic C- 
terminus (A-B), and that the C-terminus interacts with one of the two domains.  
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Figure 4.6 Digestion of HMO1 and HMO1-boxAB with BNPS-skatole.   The top panel 
is a cartoon representation of possible protein fragments sizes after digestion of HMO1 
and HMO1-boxAB with BNPS-skatole which cleaves at Trp149 and Trp160. The lower 
panel shows protein digested with BNPS-skatole in the absence or presence of 4-way 
junction DNA after electrophoresis on a 17% SDS-PAGE gel. Lanes 1 and 4 shows 
undigested protein. Lanes 2 and 5 shows protein digest in the absence of DNA. Lane 3 
and 6 show protein digested in the presence of DNA. Cleaved protein fragments are 
identified at the right in the order of descending sizes as per the top panel, 1, 2, 3, 3b and 
4b. 
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They showed the thermal melting of box A and B to be identical with transition 
temperatures of 43 ° C and 41° C, respectively, and the melting temperature of A-B had 
nearly identical transitions of 40° C and 41° C. On the other hand, full length HMGB1 
had biphasic transition values of 38° C and 55° C. The difference in the thermal melting 
temperature between A-B and HMGB1 indicated that the C-terminus interacted with one 
of the domains (as a result of increase of melting temperature from 41° C or 43°C to 
55°C), stabilizing the protein. We have shown that HMO1 and HMO1-boxAB goes 
though a biphasic thermal denaturation processes, indicative of two underlying melting 
processes. HMO1-boxA has a theoretical pI of 4.08, 15 negatively charged residues and 4 
positively charged residues, whereas HMO1-boxB has a theoretical pI of 10.07, a total of 
12 negatively charged residues and 15 positively charged residues. The C-terminal tail 
(the last 30 amino acids) has a theoretical pI of 10.07, 6 negatively charged residues and 
14 positively charged residues. The high net positive charge of the C-terminus will 
interact with the high net negative charge of box A. It is also likely that the net positive 
charges in box B will interact with high net negative charges residues in box A. The 
amount of net charge helps argue for a stronger interaction of C-terminal tail with box A 
than with box B. Therefore, it is more likely that the larger change seen in melting 
temperature due to the removal of the C-terminal tail in HMO1-boxAB is due to severed 
interaction with box A. It is also likely that with the removal of the C-terminal tail, the 
interaction of box A and box B changes.  It has been shown that removal of the basic 
region of HMGB protein increases the melting temperature of the protein [30]; an 
indication that interaction of the basic region with the protein domain lowers the melting 
temperature (destabilizes the protein). HMO1-boxA melts at 52.2 ± 0.2°C while HMO1-
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boxAB melts at 48.2 ± 2.0°C and 71.7 ± 0.7°C. Interaction of box B with box A in 
HMO1-boxAB is likely to lower the melting temperature in box A compared to an intact 
box A in HMO1-boxA. This would then imply that the first transition seen in HMO1-
boxAB represents melting of box A. Therefore, in full length HMO1, interaction of the 
C-terminal tail and box B with box A destabilizes box A, and in HMO1-boxAB, 
interaction of box B with box A destabilizes box A.  We can therefore conclude that the 
second transitions seen both in HMO1 and HMO1-boxAB represent unfolding of box B. 
It is also unlikely that HMO1 box A and box B operate as independent domains since 
both domains interact with the C-terminal tail, unlike HMGB1 [41].  
DNA binding and bending properties of HMO1-boxAB 
 Basic extensions found either C- or N-terminal to the HMG box are known to 
have a positive effect on bending capacity and DNA-binding affinity of the HMG box. 
This region stimulates binding to linear DNA and 4-way junctions, DNA supercoiling 
and circularization of short DNA fragments (reviewed in [28, 39]). For example in yeast, 
the basic N-terminus of the NHP6A HMG box is required for stable complex formation 
on both linear DNA and DNA minicircles. At high concentrations, mutants lacking the 
N-terminus are able to promote minicircle formation and Hin invertasome assembly, but 
they are unable to form stable complexes with DNA, co-activate transcription, and 
complement the growth defect of ∆nhp6a/b mutants [20]. Basic C-terminal extensions 
stabilize binding of HMG-D and LEF-1 by binding in the major groove opposite the 
distorted minor grove [8, 27]. Severe negative effect are seen when the basic N-terminal 
domains of maize and rice HMGB1 are deleted [42, 43].  In this study, we show that 
deletion of the basic C-terminus of HMO1 has a negative effect on DNA affinity. It is 
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likely that the basic C-terminus contributes to DNA affinity of this protein by directly 
interacting with the DNA since it is highly charged. Thomsen et al. showed that the 
individual basic N-terminal domain of maize HMGB1 binds DNA [30]. Here, we have 
shown that the HMO1 C-terminus interacts with both box A and box B and as such, this 
interaction could modulate HMO1 affinity for DNA. A change in DNA binding could be 
due to a net change in available charges that facilitates DNA interactions, and/or a change 
in protein conformation, enabling a better DNA protein interaction.  It has previously 
been shown that intramolecular interaction of the acidic tail and HMG-box domain(s) 
may modulate DNA interactions of HMGB proteins [28, 41, 44, 45]. It would be 
interesting to assess if the individual C-terminal tail would fold into an individual domain 
and if it would bind DNA. Although deletion of the HMO1 C-terminus does not severely 
affect HMO1 affinity for DNA, it completely abolishes its DNA bending properties 
(Figure 4.3). NHP6A and HMGB1 basic N-terminal domains have been shown to 
enhance the DNA bending properties of these proteins [20, 42], which correlates to these 
proteins DNA binding properties. It is apparent that changes in individual HMGB 
proteins in DNA binding properties correlate to changes in DNA bending properties.  
CKII phosphorylates HMO1 
 CKII has previously been used in phosphorylation of HMGB serine residues [21, 
22, 41]. CKII phosphorylates HMO1 (Figure 4.4, panel A) and HMO1-boxAB, which 
lowers the DNA affinity of these proteins, as shown using EMSA (Figure 4.4, panel B). 
Protein phosphorylation increases the negative net charge. In this study, we have shown 
that CKII phosphorylates HMO1 Ser137 and/or Ser153, both of which are located in box 
B. We have previously shown that box A binds DNA but with low affinity [35], hence 
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this strengthens the argument that box B confers most of the DNA binding affinity. 
Increasing the negative net charge in box B leads to reduction in DNA affinity. This 
phenomenon can be explained by the following possible scenarios; 1) electrostatic DNA 
repulsion, 2) increasing the negative net charge in box B leads to a stronger interaction 
with the C-terminus and as a result, the net positive charge available in box B and/or in 
the C-terminal tail that contributes to DNA binding is lowered, or 3) change in protein 
conformation and/or stability. The rate at which phosphorylation reduced HMO1 and 
HMO1-boxAB affinity for DNA looks similar (Figure 4.3), making the second scenario 
less likely since involvement (or lack thereof) of the C-terminal tail does not make a 
difference in effect that phosphorylation has in DNA binding of these proteins. It is 
interesting also to note that HMO1-boxAB does not bend DNA nor does it supercoil 
closed relaxed DNA, before or after phosphorylation (Figure 4.3, data not shown). We 
have also shown that protein cleavage with Enterokinase and BNPS-skatole does not 
confer a gross change of protein conformation in the presence of DNA or protein 
phosphorylation since cleavage patterns remain the same. Therefore, the conformational 
changes that HMO1 goes through upon DNA binding and/or after phosphorylation could 
not be detected by cleavage with Enterokinase or BNPS-skatole. It would be interesting 
to investigate the conformational changes using intrinsic fluorescence and thermal 
stability using CD spectroscopy of HMO1 before and after phosphorylation. This would 
be critical in trying to understand the role of HMO1 in vivo in its DNA interaction 
capacity, since this protein is most likely phosphorylated in vivo.  The C-terminus of 
HMO1 has been shown to be dispensible for function in vivo [31]. We have shown 
HMO1-boxAB to be localized in the cytoplasm, unlike HMO1 which is localized both in 
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the nucleus and cytoplasm (unpublished data, [31, 34]). We therefore would like to 
propose that the majority functions of HMO1 are located in the cell cytoplasm and not in 
the nucleus. Recently, the extranuclear and extracellular functions of HMGB1 have just 
started to come into focus. It participates in developmental and differentiation processes, 
triggers and modulates many of the inflammatory cascades in the body, and may even be 
involved in the metastatic invasion programme of cancer cells (reviewed in [46]). As 
such, it is more likely that post-translational modification of HMO1 (phosphorylation) 
and HMGB1 plays more crucial role(s) in regulating the function(s) of these proteins in 
the cytoplasm than in the nucleus.  
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CHAPTER 5 
FLUOROQUINOLONE-DEPENDENT DNA SUPERCOILING BY VACCINIA 
TOPOISOMERASE I 
 
Introduction  
DNA topoisomerases are ubiquitous enzymes that control DNA topology. While 
DNA cleavage by all topoisomerases leads to formation of a transient covalent 
intermediate in which a tyrosine is linked to a broken DNA strand, type I topoisomerases 
relax supercoiled DNA by cleaving only one DNA strand, causing the linking number to 
change in steps of one. The type IB enzymes, which form a covalent bond to a 3'-
phosphate, are found in all eukaryotes, where they relax both positive and negative 
supercoils [1-3]. 
 The type IB enzymes of poxviruses are the smallest topoisomerases known. 
Vaccinia topoisomerase I is a 314-amino acid protein that binds duplex DNA with 
stringent specificity for transesterification at 5'-(C/T)CCTT↓ sites, where the 3' 
phosphate of the incised strand becomes linked to Tyr-274 of the enzyme [3-7]. Vaccinia 
topoisomerase I consists of two structural modules; the N-terminal module contacts the 
cognate DNA site in the major groove, while the C-terminal module comprises an 
autonomous catalytic domain [8-11]. The structure of the catalytic domain is similar to 
that of human topoisomerase I, except for a displacement of the active site tyrosine [10-
12].  
Vaccinia encapsidates many enzymes that are needed for early viral transcription, 
including topoisomerase I. Inactivation of the gene encoding Vaccinia topoisomerase I  
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was recently shown to be associated with diminished infectivity in vitro due to reduced 
early transcription [13], suggesting that drugs that interfere with Vaccinia topoisomerase 
activity have the potential to be developed into effective antiviral agents. Vaccinia 
topoisomerase I displays unique pharmacological properties; it is resistant to 
camptothecin, otherwise a topoisomerase I poison, but sensitive to inhibitors of bacterial 
DNA gyrase such as novobiocin and coumermycin, both coumarin drugs that are used as 
antibiotics [14-19].  
Fluoroquinolones are topoisomerase II poisons known to target DNA gyrase and 
topoisomerase IV in bacterial cells [20-22]. The interaction of norfloxacin with the DNA-
gyrase complex has been investigated in some detail. While binding of norfloxacin to 
gyrase was undetectable, it was shown to bind DNA directly and to exhibit a binding 
mode involving preferred recognition of single-stranded DNA. Drug binding was 
enhanced by the presence of gyrase, suggesting that DNA-binding revealed a cryptic 
norfloxacin binding site on the enzyme [23-24]. The nature of the norfloxacin-DNA 
complex has been analyzed by several groups, with somewhat disparate conclusions. 
Norfloxacin was reported to require magnesium ions for DNA binding, with Mg2+ 
proposed to act as a bridge between the negatively charged DNA phosphates and the 
carbonyl and carboxyl moieties of norfloxacin [25]. However, more recent reports 
showed binding of norfloxacin to DNA in the absence of Mg2+ and suggested a mode of 
DNA interaction that ruled out classical DNA intercalation or groove binding, based in 
part on the observation that the molecular plane of norfloxacin is nearly perpendicular to 
the helix axis [26-27]. These authors also found that DNA unwinding by norfloxacin is 
negligible and proposed instead that the compound may induce a bend in the DNA helix.     
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The inhibitory effect of fluoroquinolones is based on their ability to stimulate the 
forward rate of the topoisomerase II-mediated DNA scission; after binding the cleavable 
complex, the fluoroquinolone induces a conformational change in the enzyme that 
prevents religation [28-30]. The fluoroquinolone derivative ofloxacin was previously 
shown also to exhibit antiviral activity against Vaccinia virus, and the inhibitory activity 
shown to correlate with inhibition of topoisomerase I purified from Vaccinia virus cores 
[31]. Here we describe a novel interaction of fluoroquinolones with Vaccinia 
topoisomerase I in vitro, focusing on enrofloxacin which is structurally closely related to 
ciprofloxacin (Figure 5.1). We show here that enrofloxacin inhibits DNA relaxation by 
Vaccinia topoisomerase I at lower concentrations than those required for inhibition by 
ofloxacin. In the presence of relaxed DNA, enrofloxacin causes Vaccinia topoisomerase I 
to supercoil DNA, reversing its action as a DNA relaxing enzyme. Notably, enrofloxacin 
does not induce human topoisomerase to supercoil relaxed DNA.   
Experimental Procedures 
Inhibition of DNA relaxation by fluoroquinolones. 
 Supercoiled closed circular pUC18 plasmid (0.2 µg) was incubated with 2.5 units 
of Vaccinia topoisomerase I (Epicentre; 10 units ~ 6 ng), wheat germ topoisomerase I 
(Promega) or human topoisomerase I (TopoGEN) and varying concentrations (2.5 µM to 
1250 µM) of enrofloxacin, ofloxacin, norfloxacin, lomefloxacin (Sigma), ciprofloxacin or 
moxifloxacin (a generous gift from Bayer Pharmaceuticals) in topoisomerase reaction 
buffer (50 mM Tris, pH 7.5, 2.5 mM MgCl2, 100 mM NaCl and 0.1 mM EDTA) for 2 
hours at 37°C. Reactions were quenched with 5 µl termination buffer (250 mM Tris-
borate, 5 mM EDTA (5X TBE), 5% SDS, 15% sucrose, 0.1% bromophenol blue (BPB),  
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Figure 5.1 Structure of fluoroquinolones. 
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0.1% xylene cyanol, 2 µg/µl proteinase K) and further incubated for 1 h at 37°C, except 
where noted. Samples were loaded on 1% 1X TBE agarose gels and electrophoresed at 2 
V/cm for 16 h in 1X TBE buffer. Gels were stained with ethidium bromide (EtBr) and 
quantified using an Alpha Innotech digital imaging system. 
Supercoiling of relaxed DNA by vaccinia topoisomerase in the presence of 
fluoroquinolones 
 
 Relaxed closed circular pUC18 plasmid was prepared by adding 2.5 units 
Vaccinia topoisomerase I to supercoiled pUC18 in topoisomerase reaction buffer for 2 h 
after which the DNA was phenol-chloroform extracted and ethanol precipitated. 
Supercoiling reactions contained 0.2 µg relaxed closed circular pUC18, 2.5 units of 
Vaccinia topoisomerase I and varying concentrations of fluoroquinolone. Reactions were 
incubated at 37°C for 2 h, quenched and electrophoresed as described above. To study the 
effects of coumermycin on supercoiling of relaxed DNA by Vaccinia topoisomerase I in 
the presence of enrofloxacin, varying concentrations of coumermycin (25 µM-500 µM) 
were incubated with topoisomerase for 10 minutes before addition of DNA and 
enrofloxacin. Reactions were analyzed as described above.  
Ligase assay with ethidium bromide and enrofloxacin 
 Ligase-mediated reactions were initiated by addition of 1 unit of T4 DNA ligase 
to a final volume of 20 µl reaction buffer (20 mM Tris-HCl pH 8, 50 mM NaCl, 10 mM 
MgCl2, 0.1 mM Na2EDTA, 1 mM DTT, 0.05% BRIJ58) containing 0.2 µg nicked DNA. 
(Nicked DNA was prepared by incubation of pUC18 DNA with N.BstNB I (NEB)). 
Increasing concentrations of EtBr or enrofloxacin were added, and reactions were 
incubated at room temperature for 3 h after which they were quenched by addition of 5 µl 
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of termination buffer and further incubated for 1 h at 37°C. Samples were analyzed as 
described above. 
Two-dimensional analysis of supercoiling 
     DNA was supercoiled by incubating 0.2 µg relaxed closed circular pUC18, 2.5 
units of Vaccinia topoisomerase I and 25 µM enrofloxacin at 37°C for 2 h followed by 
addition of termination buffer and a further incubation at 37°C for 1h. To determine the 
direction of supercoils introduced by Vaccinia topoisomerase I in the presence of 
enrofloxacin, topoisomers were separated by electrophoresis at 2 V for 16 h in 1X TBE 
buffer. The gel was soaked in chloroquine (3 µg/ml) for 1 h, turned 90° and run at 4 
V/cm for 8 h in 1X TBE buffer, then stained with EtBr and visualized as described above. 
Electrophoretic Mobility Shift Assays 
 An 18/24 duplex DNA containing a single CCCTT motif was used in this 
analysis. The top strand (18-mer, either unmodified or 5'-CGTGTCGCCCTT∗ATTCCG-
3', with the asterisk indicating phosphorothioation) was 5'-end labeled with T4 
polynucleotide kinase and [ -32P] ATP and annealed to the bottom strand (24-mer, 5'-
CACTATCGGAATAAGGGCGACACG-3'). Reactions were incubated at room 
temperature in 10 µl topoisomerase buffer (50 mM Tris-HCl pH 7.5) containing 25 nM 
DNA and varying amounts of Vaccinia topoisomerase I. Samples were adjusted to 5% 
glycerol and resolved on prerun 7% (w/v) native polyacrylamide (39:1 
acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE running buffer. Quantification was 
performed on a Molecular Dynamics Storm Phosphorimager using software supplied by 
the manufacturer. 
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Suicide substrate cleavage 
 The top strand of the non-phosphorothioated 18/24 duplex was 3'-end labeled 
with terminal transferase and [ -32P] ATP and annealed to the bottom strand. DNA 
cleavage reactions were initiated by addition of 100 units of Vaccinia topoisomerase I to 
130 µl of substrate cleavage buffer (10 mM Tris-HCl pH 7.0, 0.1 mM EDTA, 2.5 mM 
MgCl2, 2.5 mM CaCl2) containing 500 nM DNA, with or without enrofloxacin. Time 
points were taken at 0.5, 1, 5 and 10 minutes. For each time point, 10 µl of the reaction 
mixture was quenched by addition of 5 µl termination buffer and further incubated for 1 h 
at 37°C. Samples were adjusted to 70% formamide, heated for 4 minutes at 95°C and 
resolved on prerun 20% (w/v) polyacrylamide (19:1 acrylamide: bisacrylamide) 
denaturing gels with 7M urea in 0.5X TBE. Gels were visualized and quantified on a 
Molecular Dynamics Storm Phosphorimager as described above.  
Results 
Enrofloxacin inhibits DNA relation by topoisomerase I 
 Enrofloxacin inhibits relaxation of supercoiled plasmid DNA by Vaccinia 
topoisomerase I in a concentration-dependent fashion, with complete inhibition at ~1 mM 
drug (Figure 5.2). The concentration of enrofloxacin required to inhibit Vaccinia 
topoisomerase I is comparable to the effective concentration of the coumarin drugs 
novobiocin (~0.5 mM) and coumermycin (~0.2 mM) needed to inhibit DNA relaxation 
by Vaccinia topoisomerase I, but lower than the ~2 mM ofloxacin previously seen to 
elicit ~30% inhibition of topoisomerase I purified from virus cores [17, 31] Consistent 
with this observation, we also find that higher concentrations of ofloxacin are required to 
inhibit the enzyme compared to enrofloxacin (data not shown). Enrofloxacin also inhibits  
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Figure 5.2 Inhibition of DNA relaxation by enrofloxacin. Reactions contained 0.2 µg 
supercoiled pUC18, 2.5 units Vaccinia topoisomerase I, wheat germ topoisomerase I or 
human topoisomerase I and increasing concentrations of enrofloxacin (enro): 2.5, 12.5, 
62.5, 125, 250 and 1250 µM (lanes 3-9, 10-15, 17-22). Lanes 2, 9 and 16 are relaxation 
reactions with no drug added. Lane 1 is the supercoiled DNA. Relaxed (R) and 
supercoiled DNA (SC) is identified at the left. 
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relaxation of DNA by wheat germ topoisomerase I at equivalent concentrations, but does 
not produce any effects on human topoisomerase I within this concentration range 
(Figure 5.2). 
Vaccinia topoisomerase introduces negative supercoils into relaxed DNA in the presence 
of enrofloxacin 
 
  Incubation of relaxed closed circular pUC18 DNA with Vaccinia topoisomerase I 
and increasing concentration of enrofloxacin resulted in the generation of a distribution of 
supercoiled DNA topoisomers (Figure 5.3A); the distribution differs from that seen when 
DNA is relaxed by topoisomerase I. The order in which reactants were added did not 
affect the efficiency with which Vaccinia topoisomerase I supercoiled relaxed DNA 
(Figure 5.3A, lanes 12 and 13). In the presence of enrofloxacin, wheat germ 
topoisomerase I also introduced supercoils into relaxed DNA, however, a lower 
superhelical density was generated. In contrast, enrofloxacin had no effect on human 
topoisomerase I (Figure 5.3B). Note that a distinct population of topoisomers is generated 
upon incubation of relaxed DNA with human topoisomerase I, each topoisomer 
interdigitating between topoisomers produced by wheat germ or Vaccinia topoisomerase 
I (Figure 5.3B, lanes 8 and 9).  
To determine the direction of DNA superhelicity, a 2-dimensional agarose gel 
electrophoresis was performed. In the presence of chloroquine, negatively supercoiled 
DNA topoisomers, separated in the first dimension, lose superhelicity and migrate slower 
while positively supercoiled DNA gains superhelicity and migrates faster. Accordingly, 
negatively supercoiled topoisomers migrate with a left-handed curvature in the second 
dimension (e.g., Figure 5.3D), while positively supercoiled topoisomers generate a right- 
 110
                    
Figure 5.3 Supercoiling of relaxed DNA in the presence of enrofloxacin. (A) 
Reactions contained 0.2 µg relaxed pUC18, 2.5 units Vaccinia topoisomerase I, 
increasing concentrations of enrofloxacin (enro): 12.5, 25, 50, 75, 125, 175 and 250 µM 
(lanes 3-9). In lanes 10 and 11, relaxed DNA was incubated with 30 or 60 µM 
enrofloxacin. In lane 12, relaxed DNA was incubated with Vaccinia topoisomerase I for 
10 minutes, then 30 µM enrofloxacin was added and the reaction incubated further for 2 
h. In lane 13, enrofloxacin was incubated with Vaccinia topoisomerase I for 10 minutes, 
after which DNA was added and the reaction incubated further for 2 h. (B) Reaction 
mixtures are as above, except with wheat germ topoisomerase I (left panel) and human 
topoisomerase I (right panel). Lanes 3-8 and 10-15 contain enrofloxacin (7.5 – 75 µM). 
Topoisomers are identified by a bracket, relaxed (R) and supercoiled DNA (SC) is 
identified at the left. (C-F) Two-dimensional analysis of supercoiling. The direction of 
electrophoresis is indicated. (C) Relaxation of negatively supercoiled DNA by Vaccinia 
topoisomerase I yields a distribution of positively supercoiled topoisomers. (D) Negative 
supercoils introduced by Vaccinia topoisomerase I in the presence of enrofloxacin. (E) 
Positive supercoils introduced by human topoisomerase I in the presence of enrofloxacin. 
(F) Positive supercoils introduced by human topoisomerase I in absence of enrofloxacin.  
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handed arc after electrophoresis in the second dimension (e.g., Figure 5.3C). While 
relaxation by Vaccinia topoisomerase I generates a population of positively supercoiled 
topoisomers, negative supercoils are introduced in the presence of enrofloxacin (Figure 
5.3C-D). When a 2-dimensional agarose gel electrophoresis was performed on the 
population of topoisomers generated by human topoisomerase I in the presence or 
absence of enrofloxacin, positive supercoils were detected (Figure 5.3E-F). While 
ciprofloxacin and norfloxacin were as efficient as enrofloxacin at inducing the 
topoisomerase to produce DNA supercoiling, no effect was seen in the presence of 
equivalent concentrations of the structurally related compounds moxifloxacin and 
lomefloxacin (Figure 5.4), pointing to specific structural requirements for the observed 
interaction. Notably, both compounds found to be ineffective in modulating Vaccinia 
topoisomerase I activity contain a C8 substituent (a methoxy group in the case of 
moxifloxacin and fluorine for lomefloxacin (Figure 5.1)). 
Effects of coumermycin and enrofloxacin on DNA binding by Vaccinia topoisomerase I 
 Coumermycin inhibits Vaccinia topoisomerase I by blocking its interaction with 
DNA [2, 17]. Coumermycin inhibited the enrofloxacin-mediated supercoiling of relaxed 
DNA by Vaccinia topoisomerase I at concentrations similar to those required for 
inhibition of DNA relaxation (data not shown), suggesting unhindered access of 
coumermycin to its binding site in the presence of enrofloxacin and prevention of 
enzyme-DNA complex formation. 
Enrofloxacin does not modulate the Vaccinia topoisomerase I active site 
 Vaccinia topoisomerase I displays considerable DNA sequence specificity, 
binding and forming a covalent adduct at sites containing the sequence 5'- 
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Figure 5.4 Structural specificity of fluoroquinolones. Reaction mixtures are as 
described for Figure 3. except that Vaccinia topoisomerase I was incubated with (A) 
norfloxacin (0.25, 2.5, 12.5, 62.5, 125, and 250 µM in lanes 3-8), (B) moxifloxacin (2.5, 
12.5, 25, 62.5, 125, 250, and 1,250 µM in lanes 3-9) or (C) lomefloxacin (concentrations 
as for panel B). Lanes 1 contain supercoiled DNA and lanes 2 relaxed DNA. 
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(C/T)CCTT↓ [3, 9]. Suicide substrates have been useful for analysis of DNA cleavage, 
containing a single CCCTT↓ cleavage site from which a non-covalently held 6-nt product 
is released in preference to religation (Figure 5.5A) [3, 32, 33]. Electrophoretic mobility 
shift assays (EMSA) in which Vaccinia topoisomerase I bound either the suicide 
substrate or a modified version with a phosphorothioate replacing the scissile 
phosphoester bond, thus trapping the covalent intermediate and preventing religation, 
showed no interference of enrofloxacin with DNA binding and formation of the covalent 
intermediate (data not shown). We also assayed whether enrofloxacin would modify the 
rate of Vaccinia topoisomerase I-mediated DNA cleavage under single-turnover 
conditions [33]. As determined from initial rates of cleavage product release, 
enrofloxacin does not modify the rate of Vaccinia topoisomerase I-mediated DNA 
cleavage (Figure 5.5B-C). 
Enrofloxacin does not supercoil DNA 
 Although fluoroquinolones have been reported not to associate with DNA in a 
classical intercalative or groove-binding mode that leads to DNA unwinding [26, 27], 
several experiments were performed to rule out the possibility that the fluoroquinolones 
modulate DNA topology. First, relaxed DNA was incubated with increasing 
concentrations of enrofloxacin in the absence of the enzyme. At concentrations up to 60 
µM, enrofloxacin had no effect on DNA migration, arguing against an intercalative mode 
of interaction with the DNA (Figure 5.3, lanes 10 and 11). Secondly, if enrofloxacin were 
merely causing DNA unwinding, then negative supercoils would also be expected to 
result from incubation with human topoisomerase I, and that is not observed (Figure 5.3).  
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Figure 5.5. Suicide substrate assay. (A) An 18-nt CCCTT-containing oligonucleotide 
hybridized to a 24-nt oligonucleotide. (B) Reaction in lane 1 contains substrate DNA with 
no enzyme. Lanes 2-6 time-course reactions with 2.5 units of Vaccinia topoisomerase; 
reactions were terminated after 0.5, 1, 5 and 10 minutes. Lanes 7-10 are similar to 2-6, 
but contain 25 µM enrofloxacin. (C) The fraction of cleaved DNA as a function of time 
of incubation.  
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Note, however, that the reactions presented in Figures 5.2-5.4 were terminated with 
buffer containing SDS, which would be expected to disrupt interactions and release 
bound drug. Therefore, if the fluoroquinolone had induced DNA unwinding, and if the 
topoisomerase had relaxed the resulting positive DNA supercoils, then removal of bound 
drug should cause the DNA to rewind and to form negative supercoils. We tested this 
experimentally, noting that Vaccinia topoisomerase I was previously found to relax 
positive DNA supercoils preferentially (Figure 5.6) [34]. As expected, incubation of 
Vaccinia topoisomerase I with relaxed DNA in the presence of EtBr, which unwinds 
DNA ~26° upon binding [35], leads to a distribution of positively supercoiled 
topoisomers when reactions are terminated without disruption of the drug-DNA 
interactions (Figure 5.6A). Exposure of the reactions to SDS (not shown) or phenol-
extraction leads to the expected removal of EtBr and formation of negatively supercoiled 
topoisomers (Figure 5.6B). By contrast, negatively supercoiled topoisomers are formed 
on incubation of Vaccinia topoisomerase I with relaxed DNA in the presence of 
enrofloxacin, whether reactions are terminated by treatment with SDS (Figure 5.3), 
phenol-extraction (Figure 5.6D) or without disruption of the drug-DNA interaction 
(Figure 5.6C), indicating that the observed DNA supercoiling is not due to rewinding of 
DNA upon extraction of the drug. Finally, nicked pUC18 was religated with T4 DNA 
ligase in the presence of increasing concentrations of EtBr or enrofloxacin (Figure 5.6E-
F). In the presence of EtBr, religation produced different DNA topoisomers compared to 
the control, and as expected, at higher EtBr concentration, the DNA was fully 
supercoiled. When religated in the presence of enrofloxacin, the topology of the 
covalently closed DNA was not altered.  
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Figure 5.6 Enrofloxacin does not modulate DNA topology. (A-D) Two-dimensional 
analysis of DNA supercoiling. (A-B) Vaccinia topoisomerase I incubated with relaxed 
DNA and EtBr, with reactions terminated without SDS, yielding a distribution of 
positively supercoiled DNA topoisomers, as seen also for relaxation of negatively 
supercoiled DNA (Figure 3C) (A), or by phenol-extraction, resulting in negatively 
supercoiled DNA (B). (C-D) Vaccinia topoisomerase I incubated with relaxed DNA and 
enrofloxacin, with reactions terminated without SDS (C) or by phenol-extraction (D), in 
both cases yielding negatively supercoiled DNA. The direction of electrophoresis is 
indicated. (E) Ligation of nicked DNA in the presence of ethidium bromide (EtBr) or 
enrofloxacin. Lane 1 is nicked DNA and lane 2 is religated DNA. Lanes 3-6 are ligation 
of nicked DNA with 0.5, 1, 2 and 4 µM EtBr, lanes 7-10 are religation of nicked DNA 
with 25, 37.5, 75 and 125 µM enrofloxacin. Topoisomers are identified by a bracket. (F) 
Two-dimensional analysis of DNA topoisomers formed by ligation of nicked DNA in the 
presence of EtBr. 
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Discussion 
 To relax DNA, Vaccinia topoisomerase I binds non-covalently to duplex DNA 
and cleaves one DNA strand with concomitant formation of a transient covalent DNA-
protein intermediate, followed by DNA topological changes and religation. The data 
presented here show that in the presence of specific fluoroquinolones, Vaccinia 
topoisomerase I reverses its role as a DNA relaxing enzyme and introduces DNA 
supercoils. As demonstrated for norfloxacin [26, 27], enrofloxacin would also be 
expected to bind DNA without inducing significant unwinding (Figure 6). Since the rate 
of formation of the covalent topoisomerase-DNA intermediate is equivalent in the 
presence or absence of enrofloxacin (Figure 5), we find it less likely that the 
topoisomerase binds a preformed DNA-fluoroquinolone complex, and propose instead 
that the compound may bind preferentially to DNA that has undergone structural 
distortions due to enzyme binding (as suggested for targeting of fluoroquinolones to a 
DNA-gyrase complex) [23, 24]. Our data also suggest that Vaccinia topoisomerase I 
would bind and cleave its cognate DNA sequence in the presence of the fluoroquinolone, 
with steps beyond formation of the transient covalent intermediate modulated by the 
drug. 
 Vaccinia topoisomerase I, which removes an average of five superhelical turns 
per cleavage and religation event, was proposed to do so by a free rotation mechanism in 
which the non-covalently held DNA swivels in an energetically favorable process to 
relieve superhelical tension [32]. In contrast, type II topoisomerases are ATP-dependent 
and are believed to operate as molecular clamps, forming an enzyme-operated gate in one 
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double-stranded DNA segment and passing the other DNA segment through this gate [36, 
39]. DNA gyrase introduces negative supercoils into DNA, a feature that requires the 
enzyme to dictate the directionality of strand passage. The mechanism of 
fluoroquinolone-mediated supercoiling of DNA by Vaccinia topoisomerase I cannot 
involve free rotation because first, supercoiling of DNA is not energetically favorable, yet 
this process is ATP-independent, and second, introduced supercoils are negative, 
indicating that the enzyme dictates directionality. As the fluoroquinolones have been 
shown not to bind DNA in a classical mode that results in DNA underwinding (Figure 6) 
[26, 27], and since the observed effect is not a general property of all fluoroquinolones 
(Figure 4), we suggest that topological changes in the DNA are driven by protein 
interactions. 
 The N-terminal domain of Vaccinia topoisomerase I interacts with the DNA 
major groove while the catalytic C-terminal domain interacts with the minor grove on the 
face of the helix that contains the scissile phosphodiester [40]. DNA binding triggers a 
conformational change at the interdomain linker, causing Vaccinia topoisomerase I to 
bind DNA circumferentially as a C-shaped protein clamp [8-10, 40].  It is possible that 
the fluoroquinolone interferes with these conformational changes; the enzyme may adopt 
a conformation that does not alter its catalytic activity, yet introduces structural changes 
that enables it to wrap the DNA in a toroidal supercoil. The mechanism of free rotation of 
DNA to release superhelical tension was proposed in part based on the observation that a 
2-6 nt 3'-fragment dissociates in preference to religation and that only 2 bp 3' to the 
cleavage site is required for cleavage [4, 41]. However, the enzyme does protect at least 
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13 bp downstream of its cleavage site [5]. Whereas these interactions may not be required 
for cleavage, our data are consistent with their role in topological changes or religation. 
 Enrofloxacin does not mediate DNA supercoiling by human topoisomerase I 
(Figure 3B). In contrast to Vaccinia topoisomerase I, human topoisomerase I is proposed 
to follow a “controlled rotation” mechanism for DNA relaxation, in which ionic 
interactions between DNA and protein regulate the DNA winding process [12, 42]. In our 
relaxation assays, we obtained the typical Gaussian distribution of positively supercoiled 
topoisomers that did not change in the presence of enrofloxacin (Figure 3). The formation 
of positively supercoiled topoisomers is consistent with a controlled rotation of DNA in 
which contacts to the enzyme, possibly downstream of the cleavage site, serve to orient 
the DNA. A difference in mechanism of DNA relaxation between Vaccinia 
topoisomerase I and human topoisomerase I may contribute to the differential effects of 
enrofloxacin on these two enzymes. Alternatively, the binding site for fluoroquinolones 
may be obscured or poorly conserved in the human enzyme. Distinct pharmacological 
properties are indeed characteristic of Vaccinia topoisomerase I, which is resistant to 
classical topoisomerase I poisons, but sensitive to other gyrase inhibitors such as 
coumermycin [2, 17]. 
 The recent observation that inactivation of the gene encoding Vaccinia 
topoisomerase I causes decreased infectivity suggests that compounds that target this 
enzyme have therapeutic potential [13]. Our data suggest that fluoroquinolones may be 
structurally optimized to target poxvirus topoisomerases and to serve as antiviral agents. 
This notion is corroborated by a previous report showing that the fluoroquinolone 
ofloxacin has selective, antiviral activity against Vaccinia virus in cultured mammalian 
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cells [31]. The potential for optimizing fluoroquinolone compounds as antiviral agents 
against poxviruses is particularly significant in the face of the threat associated with the 
use of smallpox as a biological weapon.  
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CHAPTER 6 
SUMMARY AND CONCLUSION 
 Orchestration of DNA topology is critical in diverse cellular processes and its 
manipulation has been shown to be one of the central roles played by HMGB proteins 
and topoisomerases. For example, it has been shown that the chromosome of Escherichia 
coli is maintained in a negatively supercoiled state, and supercoiling levels are affected 
by growth phase and a variety of environmental stimuli [1]. A recent study measured the 
transcriptional response to a loss of supercoiling caused either by genetic impairment of a 
topoisomerase or addition of specific topoisomerase inhibitors during log-phase growth 
in E. coli and identified genes whose changes are statistically significant. Transcription of 
7% of the genome (306 genes) was rapidly and reproducibly affected by changes in the 
level of supercoiling [2]. Thus, the global control of transcription throughout the life 
cycle of an organism can be formalized as an interacting network of gene products and 
effectors that control RNA polymerase selectivity and effective superhelicity. These 
effectors can be proteins, including the HMGB proteins or compounds such as 
fluoroquinolones. To better understand this complex puzzle, we characterized HMO1, a 
Saccharomyces cerevisiae HMGB protein. We looked at its DNA binding and bending 
properties as well its posttranslational modification. We also looked at the effect 
fluoroquinolone drugs have in influencing Vaccinia topoisomerase I ability to change 
DNA superhelicity.  
HMO1 Interaction with DNA  
 Lu J et al. [3] initially characterized HMO1, indicating that it is required for 
normal growth, plasmid maintenance and for regulating the susceptibility of yeast 
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chromatin to nuclease. In this work, we show that HMO1 binds linear duplex DNA in a 
non-sequence specific manner, and that its divergent box A domain participates in DNA 
interactions. While the box A domain contributes modest structure-specific binding, the 
box B domain is required for high-affinity binding. HMO1 has only modest preference 
for DNA with altered conformations, including DNA with nicks, gaps, overhangs or 
loops, as well as for 4-way junction structures and supercoiled DNA. HMO1 binds 4-way 
junctions with half-maximal saturation of 19.6±2.2 nM, with only a modest increase in 
affinity in the absence of magnesium ions (half-maximal saturation 6.1±1.1 nM). When 
HMO1 was phosphorylated with Casein Kinase II (CKII), its DNA binding affinity was 
slightly reduced in 4-way junction DNA. Lack of preference for the 4-way junction was 
also seen by Yen Y et al. [4] in the non-histone protein 6A (NHP6A). However, binding 
to the 4-way junctions DNA is considered to be a common property of the HMGB 
proteins (reviewed in [5]).  
 Ligase-mediated circularization of small DNA fragments has been extensively 
utilized as a means of comparing the DNA bending activities of non-sequence specific 
DNA bending proteins. Both HMGB1/2 and NHP6A/B catalyze formation of 66 bp 
circles, NHP6A/B being more efficient, which has been attributed to the relative stability 
of NHP6A/B-DNA complexes compared to HMGB1/2 and HU complexes [6, 7]. 
However, this could also be due to a difference in the bend angle exerted by these 
proteins, with the angle exerted by NHP6A/B facilitating DNA strand recognition by 
ligase [6]. HMO1 facilitated formation of circles only with DNA longer than 87 bp DNA, 
a lower efficiency that may correspond to either a reduced bend angle or a short residence 
time of HMO1 on linear DNA.  
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 Work by Lu J et al. [3] reported that HMO1 introduces negative supercoils into 
relaxed plasmid DNA, and that at high concentrations, HMO1 inhibited the unwinding 
reaction. We did not find evidence that HMO1, either phosphorylated or non-
phosphorylated, have the capability to introduce supercoils into relaxed plasmid DNA. 
This can be explained by the lack of an important intercalating hydrophobic residue 
found in many HMGB proteins, but missing in HMO1 box B and SRY (an HMGB 
protein that also does not supercoil DNA). 
Phosphorylation of HMO1 
 Casein kinase II (CKII) has previously been used in phosphorylation of HMGB 
serine residues [8, 9, 10]. We have shown in our study that CKII phosphorylates HMO1 
and HMO1-boxAB but not HMO1-boxA.  Protein phosphorylation increases the negative 
net charge, altering the conformation, stability and DNA binding properties of proteins. 
Phosphorylated HMO1 and HMO1-boxAB had reduced affinity for DNA.  
HMO1 Thermal Stability 
 Thermal stability of HMO1 and HMO1-boxAB was measured by CD 
spectroscopy. We have shown that HMO1 and HMO1-boxAB goes though a biphasic 
thermal denaturation process, but that HMO1-boxA has a single transition. Our data 
strongly suggests that the C-terminal tail interacts with both box A and box B, lowering 
the melting temperature of these domains. This phenomenon, that the basic extensions of 
an HMGB protein cause a reduction of melting temperature, has been reported elsewhere 
[11]. We have also concluded from our data that the first transition seen in both HMO1 
and HMO1-boxAB is melting of box A and the second transition is melting of box B. 
However, purification and characterization of box B would address this interpretation. 
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Phosphorylation of HMGB proteins has shown that phosphates contribute to stability of 
the protein [12]. It would also be interesting to look at the effect of phosphorylation on 
stability of HMO1 and HMO1-boxAB. 
HMO1 Cellular Localization 
 The C-terminus of HMO1 is dispensible for function in vivo [3]. We have 
localized HMO1 without the C-terminus (HMO1-boxAB) to the cytoplasm. This is a 
clear indication that the essential and unique functions of HMO1 are located in the 
cytoplasm and not in the nucleus, and especially since HMO1 has weak DNA binding 
and bending properties compared to other HMGB proteins. This data is supported by the 
fact that HMO1 genetically and physically interacts with cytoplasmically expressed 
FKBP12 Prolyl Isomerase,  a product of the FPR1 gene, which when mutated has been 
shown to be synthetic lethal with ∆hmo1[13]. 
 HMGB1 is a nuclear, extranuclear and extracellular protein that participates in 
many signaling processes in the cell. (reviewed in [14]). Interesting, our data implicate 
HMO1 to function in the extranuclear maybe at similar capacity as HMGB1. Notably, 
signaling by TOR (Target of Rapamycin) kinases is central to environmental stress 
responses in yeast. Suppression of TOR signaling, for example through inhibition of TOR 
kinases by interaction with FKBP12-rapamycin, leads to cell cycle arrest (reviewed in 
[15]). The reported interaction between HMO1 and FKBP12 suggest a possible role for 
HMO1 in such signaling pathways. Studies to characterize the extranuclear function of 
HMO1 will further expand signalling roles of HMGB proteins beyond HMGB1, which 
thus far is the only HMGB protein that has been shown to have signaling capabilities, 
expanding the importance of HMGB proteins across organisms.  
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Vaccinia Topoisomerase I Supercoils DNA in the Presence of Fluoroquinolones 
 Vaccinia topoisomerase I is a site-specific DNA strand transferase that acts 
through a DNA-(3'-phosphotyrosyl)-enzyme intermediate, resulting in relaxation of 
supercoiled DNA. Although Vaccinia topoisomerase I is not an essential enzyme, its role 
in early transcription makes it a potential antiviral target. We have shown that Vaccinia 
topoisomerase I interact with enrofloxacin and a few other fluoroquinolone compounds, 
and that these compounds inhibit DNA relaxation.  When Vaccinia topoisomerase I is 
presented with relaxed DNA in the presence of enrofloxacin, it executes the reverse 
reaction, supercoiling the DNA. However, the function does not interfere with the 
catalytic cleavage site, nor does it interfere with enzyme’s ability to bind DNA. The 
mechanism with which Vaccinia topoisomerase I supercoils relaxed DNA, an 
energetically unfavorable, yet ATP-independent process, must entail protein-DNA 
contacts downstream of the cleavage site, as opposed to the free rotation mechanism 
proposed for DNA relaxation. These characteristics of Enrofloxacin-Vaccinia 
topoisomerase I interactions presents a tool to study conformational dynamics of 
topoisomerase I.  
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